500three years0001849853true--12-31three years630FYthree years0001849853stvn:IndirectControlMemberstvn:SVMAutomatikASMember2021-01-012021-12-310001849853ifrs-full:EliminationOfIntersegmentAmountsMember2021-01-012021-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:InterSegmentMember2020-01-012020-12-310001849853stvn:RestrictedStockGrantPlan20212027Member2021-01-012021-12-310001849853srt:SouthAmericaMember2020-12-310001849853country:MX2021-12-310001849853stvn:SellingAndMarketingExpensesMember2019-01-012019-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMember2020-12-310001849853ifrs-full:CostOfSalesMember2021-01-012021-12-310001849853ifrs-full:PropertyPlantAndEquipmentMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:EquityMovementsDueToEarlyTerminationOfIncentivePlansMember2021-01-012021-12-310001849853stvn:MedicalGlassASMemberstvn:IndirectControlMember2020-01-012020-12-310001849853stvn:EngineeringSegmentMemberstvn:EuropeMiddleEastAndAfricaMember2021-01-012021-12-310001849853stvn:CashAndCashEquivalentMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:SwissfillonAGMember2021-10-222021-10-220001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853stvn:PlantAndMachineryMemberstvn:DepreciationAndImpairmentMember2020-01-012020-12-310001849853country:US2019-01-012019-12-310001849853stvn:BankLoansMemberstvn:DueOn2023Member2020-01-012020-12-310001849853stvn:OtherContainmentAndDeliverySolutionsMember2020-01-012020-12-310001849853stvn:EmployeeBenefitsMember2020-12-310001849853stvn:CashSettledAwardsPeriodTwoMemberstvn:CashSettledAwardsMember2021-01-012021-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberstvn:AmortizationMember2021-12-310001849853ifrs-full:RetainedEarningsMember2020-01-012020-12-310001849853ifrs-full:LandAndBuildingsMemberstvn:DepreciationAndImpairmentMember2021-12-310001849853stvn:OmpiOfJapanCoLtdMember2018-01-012018-12-310001849853stvn:EngineeringSegmentMembersrt:AsiaPacificMember2020-01-012020-12-310001849853stvn:MedicalGlassASMember2021-01-012021-12-310001849853ifrs-full:ReserveOfCashFlowHedgesMember2018-12-310001849853ifrs-full:GoodsOrServicesTransferredOverTimeMember2021-01-012021-12-310001849853stvn:LongTermIncentivePlanPeriodTwoMemberstvn:LongTermIncentivePlanMember2020-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2021-12-310001849853stvn:CurrentFinancialLiabilitiesMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMembercurrency:JPY2020-12-310001849853stvn:OtherCurrentFinancialAssetsMemberifrs-full:CurrencyRiskMembercurrency:USDstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMember2021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:SouthAmericaMember2020-01-012020-12-310001849853stvn:DerivativesFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:LeaseLiabilityMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001849853stvn:IndirectControlMemberstvn:BaldaCBrewerIncMember2020-01-012020-12-310001849853stvn:CurrentFinancialLiabilitiesMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2020-12-310001849853stvn:PersonnelExpensesMember2019-01-012019-12-310001849853ifrs-full:BuildingsMember2021-12-310001849853stvn:OtherCurrentFinancialAssetsMemberifrs-full:CurrencyRiskMembercurrency:USDstvn:ForwardForeignExchangeContractsMember2020-12-310001849853ifrs-full:UnallocatedAmountsMember2020-12-310001849853country:CN2019-01-012019-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMember2020-12-310001849853country:MXifrs-full:LandAndBuildingsMember2021-01-012021-12-310001849853country:CH2020-01-012020-12-310001849853stvn:InVitroDiagnosticConsumablesDrugDeliverySystemsMember2020-12-310001849853country:MX2021-01-012021-12-310001849853ifrs-full:TreasurySharesMember2021-03-040001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:AsiaPacificMember2020-01-012020-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:BankOverdraftMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2021-01-012021-12-310001849853stvn:SeverancePaymentSlovakiaMember2019-12-310001849853stvn:BankLoansMemberstvn:DueOn2022Member2021-01-012021-12-310001849853stvn:DCSAndIVDDDSMember2020-12-310001849853ifrs-full:RevaluationSurplusMember2021-12-310001849853stvn:EuropeMiddleEastAndAfricaMember2021-01-012021-12-310001849853stvn:AmortizationMemberstvn:IndustrialPatentsAndIntellectualPropertyRightsMember2021-01-012021-12-310001849853stvn:MarkToMarketInterestRateSwapDerivativesMemberstvn:BankLoansMemberifrs-full:InterestRateRiskMember2021-12-310001849853stvn:FondazioneStevanatoMember2021-01-012021-12-310001849853stvn:AmortizationMember2021-01-012021-12-310001849853ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853stvn:CurrentFinancialLiabilitiesMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:JPY2020-12-310001849853stvn:SocietaAgricolaStellaSRLMember2019-01-012019-12-310001849853ifrs-full:MaterialReconcilingItemsMemberstvn:InterSegmentMember2019-01-012019-12-310001849853stvn:EngineeringSegmentMemberstvn:EuropeMiddleEastAndAfricaMember2019-01-012019-12-310001849853stvn:LaterThanFiveYearsAndNotLaterThanSixYearsMember2020-01-012020-12-310001849853stvn:NordeaBankOnBehalfOfSVMAutomatikASMember2021-01-012021-12-310001849853stvn:BaldaMedicalGmbhMemberstvn:DirectControlMember2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:AssetsUnderConstructionAndAdvancesMember2019-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberstvn:IndustrialEquipmentMember2021-01-012021-12-310001849853ifrs-full:OtherReservesMember2020-06-112020-06-110001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMember2021-12-310001849853stvn:PersonnelExpensesMember2020-01-012020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2020-01-012020-12-310001849853stvn:PlantAndMachineryMemberifrs-full:GrossCarryingAmountMember2020-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:BorrowingsFromBanksMember2020-12-310001849853stvn:LeaseLiabilityMember2020-12-310001849853stvn:PlantAndMachineryMemberstvn:DepreciationAndImpairmentMember2019-12-310001849853stvn:TangibleAssetsMember2021-12-310001849853ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2020-12-310001849853stvn:CustomerMemberstvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMember2021-01-012021-12-310001849853country:DK2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IndustrialEquipmentMember2020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMember2021-12-310001849853stvn:JubileeBenefitsMember2019-12-310001849853ifrs-full:UnusedTaxLossesMember2021-12-310001849853ifrs-full:TreasurySharesMember2020-12-310001849853stvn:ForwardForeignExchangeContractsMemberstvn:ExchangeRateSensitivityEuroOneMember2021-01-012021-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:OtherLiabilityMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2020-12-310001849853stvn:BankLoansMemberstvn:DueOn2022Member2021-12-310001849853country:CH2020-12-310001849853stvn:StevanatoSergioMember2019-01-012019-12-310001849853stvn:EngineeringSystemsMember2021-12-310001849853ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2021-01-012021-12-310001849853stvn:BankLoansMemberstvn:DueOn2025Member2020-01-012020-12-310001849853stvn:NotesMemberstvn:DueOn2028Member2021-01-012021-12-310001849853ifrs-full:TopOfRangeMember2021-12-310001849853stvn:DirectControlMemberstvn:OmpiOfJapanCoLtdMember2021-01-012021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMember2019-12-310001849853stvn:DirectControlMemberstvn:OmpiOfJapanCoLtdMember2020-01-012020-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853ifrs-full:SellingGeneralAndAdministrativeExpenseMemberstvn:CashSettledAwardsPeriodFourMember2021-01-012021-12-310001849853stvn:OmpiDoBrasilICDeEmFarLtdaMemberstvn:DirectControlMember2020-01-012020-12-310001849853stvn:EngineeringSegmentMembersrt:AsiaPacificMember2019-01-012019-12-310001849853stvn:CreditInstitutionsAndInsuranceCompaniesMember2021-12-310001849853stvn:IndustrialAndCommercialEquipmentMember2020-12-310001849853ifrs-full:MaterialReconcilingItemsMember2021-01-012021-12-310001849853stvn:IndirectControlMemberstvn:InnoscanASMember2020-01-012020-12-310001849853ifrs-full:RetainedEarningsMember2019-01-012019-12-310001849853stvn:NotesMemberstvn:DueOn2027Member2021-01-012021-12-310001849853stvn:JubileeBenefitsMember2021-12-310001849853stvn:MedicalGlassASMember2020-01-012020-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMemberstvn:InterSegmentMember2019-01-012019-12-310001849853stvn:IndirectControlMemberstvn:OmpiOfAmericaIncMember2020-01-012020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-01-012020-12-310001849853srt:AsiaPacificMember2021-12-310001849853ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2021-01-012021-12-310001849853stvn:OtherKeyManagementMember2020-01-012020-12-310001849853stvn:MedicalGlassASMember2021-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:LeaseLiabilityMember2020-12-310001849853stvn:UnicreditAGOnBehalfOfBaldaMedicalGmbhMember2020-01-012020-12-310001849853stvn:ProvisionsMember2020-12-310001849853stvn:DueOn2022Memberstvn:OverDraftsMember2021-01-012021-12-310001849853stvn:SFEMItaliaSRLMember2021-12-310001849853stvn:AmortizationMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2020-12-310001849853stvn:ReserveOfRemeasurementsOfDefinedBenefitPlansAndAgentTerminationPlanMember2020-01-012020-12-310001849853country:ITstvn:NuovaOmpiSRLMember2020-01-012020-12-310001849853stvn:InterestRateSensitivityOneMember2020-01-012020-12-310001849853stvn:SeniorNotesSeriesADueApril162028Member2020-04-162020-04-160001849853ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2019-12-310001849853stvn:CurrentFinancialLiabilitiesMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:JPY2020-01-012020-12-310001849853ifrs-full:InterestRateRiskMemberstvn:FinancialPayablesForShareAcquisitionMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:AssetsUnderConstructionAndAdvancesMember2021-01-012021-12-310001849853stvn:ProvisionForAgentsAndDirectorsSeveranceIndemnityMember2021-12-310001849853ifrs-full:EquityAttributableToOwnersOfParentMember2018-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberstvn:AmortizationMember2020-12-310001849853stvn:DueOn2027Memberstvn:BankLoansMember2021-12-310001849853ifrs-full:SellingGeneralAndAdministrativeExpenseMember2019-01-012019-12-310001849853stvn:IndirectControlMemberstvn:InnoscanASMember2021-01-012021-12-310001849853stvn:PlantAndMachineryMember2021-12-310001849853ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001849853ifrs-full:GoodsOrServicesTransferredOverTimeMember2020-01-012020-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberstvn:AmortizationMember2020-12-310001849853srt:SouthAmericaMember2019-01-012019-12-310001849853stvn:HoldingSegmentMemberifrs-full:MachineryMember2021-01-012021-12-310001849853stvn:SecuredGuaranteesMember2021-12-310001849853stvn:SEHoldingsCoLtdMember2020-01-012020-12-310001849853stvn:CashAndCashEquivalentMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:CashSettledAwardsMember2021-01-012021-12-310001849853stvn:OmpiOfJapanCoLtdMember2019-01-012019-12-310001849853stvn:NotesMember2020-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberifrs-full:GrossCarryingAmountMember2020-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:OtherFinancialLiabilitiesMember2020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMember2019-12-310001849853stvn:CTSStudioAsMember2021-01-012021-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2021-01-012021-12-310001849853ifrs-full:ReserveOfCashFlowHedgesMember2020-01-012020-12-310001849853stvn:EngineeringSegmentMembersrt:SouthAmericaMember2020-01-012020-12-310001849853stvn:NotesMember2020-12-310001849853stvn:AssociateMemberstvn:SwissfillonAGMember2020-01-012020-12-310001849853stvn:NotesMemberifrs-full:LaterThanFiveYearsMember2020-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:DerivativesFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:IssuedCapitalMember2020-12-310001849853stvn:OtherContainmentAndDeliverySolutionsMember2021-01-012021-12-310001849853stvn:OtherCurrentFinancialAssetsMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:USD2021-01-012021-12-310001849853stvn:FinancialLiabilitiesDueToRelatedPartiesMemberifrs-full:FixedInterestRateMemberifrs-full:InterestRateRiskMember2021-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2019-01-012019-12-310001849853ifrs-full:LaterThanFiveYearsMemberstvn:OtherLiabilityMember2020-12-310001849853stvn:LeaseLiabilityMemberifrs-full:LaterThanFiveYearsMember2020-12-310001849853country:CH2021-01-012021-12-310001849853ifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMember2020-12-310001849853stvn:InvestmentInBiologixPartnersLPMember2020-12-310001849853stvn:CashSettledAwardsPeriodTwoMemberstvn:CashSettledAwardsMember2020-01-012020-12-310001849853stvn:CurrentFinancialLiabilitiesMembercurrency:CHFifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2020-12-310001849853ifrs-full:RetainedEarningsMember2018-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberstvn:DepreciationAndImpairmentMember2021-12-310001849853stvn:ExecutivesMember2019-01-012019-12-310001849853ifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMember2021-12-310001849853stvn:DueOn2025Memberstvn:BankLoansMember2021-01-012021-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:OtherFinancialLiabilitiesMember2021-12-310001849853ifrs-full:MaterialReconcilingItemsMember2021-12-310001849853ifrs-full:ActuarialAssumptionOfDiscountRatesMember2021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BuildingsMember2020-01-012020-12-310001849853ifrs-full:EliminationOfIntersegmentAmountsMember2020-01-012020-12-310001849853stvn:NotesMemberstvn:DueOn2027Member2020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMember2020-01-012020-12-310001849853ifrs-full:OrdinarySharesMember2021-12-310001849853stvn:MedicalGlassASMember2019-01-012019-12-310001849853stvn:BankLoansMemberifrs-full:FixedInterestRateMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMember2019-01-012019-12-310001849853ifrs-full:OtherIntangibleAssetsMemberstvn:AmortizationMember2021-12-3100018498532021-07-012021-07-010001849853stvn:BankLoansMemberstvn:DueOn2022Member2020-01-012020-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberifrs-full:GrossCarryingAmountMember2021-12-310001849853stvn:OtherTangibleAssetsMember2020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMember2020-01-012020-12-310001849853stvn:ExchangeRateSensitivityUsDollarMemberstvn:ForwardForeignExchangeContractsMember2020-01-012020-12-310001849853stvn:BorrowingsFromBanksMember2021-12-310001849853stvn:ReserveOfRemeasurementsOfDefinedBenefitPlansAndAgentTerminationPlanMember2021-01-012021-12-310001849853stvn:MedicalGlassASMember2020-12-310001849853stvn:NotesMember2021-12-310001849853stvn:OtherTangibleAssetsMemberstvn:DepreciationAndImpairmentMember2020-12-310001849853ifrs-full:OtherReservesMember2019-06-282019-06-280001849853stvn:MarkToMarketInterestRateSwapDerivativesMemberifrs-full:InterestRateRiskMember2021-12-310001849853stvn:CustomerMemberifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2019-01-012019-12-310001849853ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMemberstvn:EngineeringSystemsMember2021-01-012021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BuildingsMember2021-01-012021-12-310001849853ifrs-full:OtherIntangibleAssetsMember2021-12-310001849853stvn:IntangibleFixedAssetsInProcessAndAdvancesMember2021-12-310001849853stvn:ExchangeRateSensitivityOneMemberstvn:ForwardForeignExchangeContractsMember2020-01-012020-12-310001849853ifrs-full:OtherIntangibleAssetsMember2020-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:InterSegmentMember2021-01-012021-12-310001849853stvn:IntangibleFixedAssetsInProcessAndAdvancesMember2020-12-310001849853stvn:ExchangeRateSensitivityMexicanPesosMemberstvn:ForwardForeignExchangeContractsMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2019-12-310001849853stvn:ActuarialAssumptionOfTurnoverRatesMember2021-12-310001849853stvn:CashSettledAwardsMember2020-12-310001849853ifrs-full:LegalProceedingsProvisionMember2019-12-310001849853stvn:AmortizationMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2020-12-310001849853stvn:IndirectControlMemberstvn:OmpiPharmPackingTechnCoLtdMember2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:EuropeMiddleEastAndAfricaMember2021-01-012021-12-310001849853stvn:HighValueSolutionsMember2020-01-012020-12-310001849853ifrs-full:OtherIntangibleAssetsMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001849853ifrs-full:InterestRateRiskMemberstvn:FinancialLiabilitiesDueToOtherLendersMember2021-12-310001849853stvn:UnicreditAGOnBehalfOfBaldaMedicalGmbhMember2021-01-012021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMemberstvn:InterSegmentMember2019-01-012019-12-310001849853stvn:MJBConsultantsLLCMember2021-01-012021-12-310001849853ifrs-full:AssociatesMember2020-12-310001849853stvn:LongTermIncentivesMember2021-12-310001849853stvn:OmpiOfJapanCoLtdMember2020-01-012020-12-310001849853country:CH2019-12-310001849853stvn:BankLoansMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-12-310001849853stvn:DirectControlMemberstvn:SpamiSRLMember2021-01-012021-12-310001849853stvn:BankLoansMemberifrs-full:InterestRateRiskMember2021-12-310001849853stvn:IncogBiopharmaServicesIncMember2021-12-310001849853country:CN2021-12-310001849853srt:NorthAmericaMember2021-01-012021-12-310001849853ifrs-full:LaterThanFiveYearsMember2021-12-310001849853stvn:OtherCurrentFinancialAssetsMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:JPY2021-12-310001849853stvn:NuovaOmpiSRLMemberstvn:DirectControlMember2021-01-012021-12-310001849853ifrs-full:PropertyPlantAndEquipmentMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001849853stvn:FinancialLiabilitiesDueToRelatedPartiesMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:SFEMItaliaSRLMember2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:MachineryMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:SwissfillonAGMember2020-12-310001849853stvn:SeverancePaymentSlovakiaMember2020-12-310001849853ifrs-full:EquityAttributableToOwnersOfParentMember2019-01-012019-12-310001849853ifrs-full:LegalProceedingsProvisionMember2021-01-012021-12-310001849853stvn:GeneralAndAdministrativeExpensesMember2019-01-012019-12-310001849853stvn:MachineryIndustrialEquipmentAndVehiclesMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001849853ifrs-full:CostOfSalesMember2020-01-012020-12-310001849853ifrs-full:WarrantyProvisionMember2020-01-012020-12-310001849853stvn:BankLoansMemberifrs-full:InterestRateRiskMember2021-01-012021-12-310001849853stvn:StudioLegaleSpinazziAzzaritaTroiMember2021-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMemberstvn:InterSegmentMember2020-01-012020-12-3100018498532021-08-182021-08-180001849853stvn:UnsecuredGuaranteesMember2020-12-310001849853ifrs-full:OtherIntangibleAssetsMemberstvn:AmortizationMember2020-12-310001849853stvn:EngineeringSegmentMemberstvn:CustomerMemberifrs-full:OperatingSegmentsMember2020-01-012020-12-310001849853ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2020-01-012020-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:TradePayablesMember2021-12-310001849853stvn:DirectControlMemberstvn:OmpiNASDeRLDeCVMember2020-01-012020-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853stvn:OmpiOfJapanCoLtdMember2019-01-012019-12-310001849853stvn:EngineeringSegmentMemberstvn:RevenuesFromEngineeringMember2020-01-012020-12-310001849853ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2021-12-310001849853ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2021-01-012021-12-310001849853stvn:WincklerCoLtdMember2019-01-012019-12-3100018498532021-07-010001849853stvn:BeneficioPorRetiroTerminacionMember2019-12-310001849853stvn:EngineeringSegmentMemberstvn:EuropeMiddleEastAndAfricaMember2020-01-012020-12-310001849853stvn:MarkToMarketInterestRateSwapDerivativesMemberstvn:BankLoansMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:PlantAndMachineryMember2021-01-012021-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberstvn:AmortizationMember2019-12-310001849853country:JP2020-12-3100018498532021-03-040001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310001849853stvn:EmployeesMember2021-01-012021-12-310001849853stvn:RevaluationsOfInvestmentPropertiesToFairValueMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2020-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:DerivativesFinancialLiabilitiesMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:BankOverdraftMember2020-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberstvn:AmortizationMember2019-12-310001849853stvn:CashSettledAwardsMember2019-01-012019-12-310001849853stvn:DueFromYearOneToYearSevenMemberstvn:BankLoansMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-12-310001849853stvn:AccrualsAndOtherProvisionsMember2021-12-3100018498532019-12-310001849853srt:AsiaPacificMember2020-12-310001849853stvn:StevanatoGroupNASDeRLDeCVMemberstvn:IndirectControlMember2021-01-012021-12-310001849853ifrs-full:MaterialReconcilingItemsMemberstvn:InterSegmentMember2020-01-012020-12-310001849853stvn:ExecutivesMember2021-01-012021-12-310001849853ifrs-full:TreasurySharesMemberstvn:RestrictedStockGrantPlan20212027Member2021-06-030001849853ifrs-full:ParentMember2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-01-012020-12-310001849853currency:CHFstvn:CurrentFinancialLiabilitiesMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMember2020-12-310001849853ifrs-full:RetainedEarningsMember2019-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberstvn:DepreciationAndImpairmentMember2020-12-310001849853country:IT2021-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:DerivativesFinancialLiabilitiesMemberifrs-full:RecurringFairValueMeasurementMember2021-12-3100018498532021-01-012021-12-310001849853stvn:NotesMember2021-12-310001849853stvn:NordeaBankOnBehalfOfSVMInnoscanASMember2020-01-012020-12-310001849853ifrs-full:TreasurySharesMember2021-12-310001849853stvn:BankOverdraftMemberifrs-full:InterestRateRiskMember2021-01-012021-12-310001849853stvn:MedirioSAMemberstvn:IndirectControlMember2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:EuropeMiddleEastAndAfricaMember2019-01-012019-12-310001849853stvn:AssociateMemberstvn:SwissfillonAGMember2021-01-012021-12-310001849853ifrs-full:NoncontrollingInterestsMember2019-01-012019-12-310001849853stvn:SVMAutomatikASMember2020-01-012020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-01-012021-12-310001849853srt:AsiaPacificMember2020-01-012020-12-310001849853ifrs-full:EquityAttributableToOwnersOfParentMember2020-01-012020-12-310001849853stvn:LongTermIncentivePlanMember2021-01-012021-12-3100018498532021-12-310001849853stvn:NotesMemberstvn:DueOn2027Member2021-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2020-01-012020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BuildingsMember2020-12-310001849853stvn:WorkInProgressMember2020-12-310001849853stvn:ForeignExchangeForwardContractsMember2020-12-310001849853stvn:GeneralAndAdministrativeExpensesMember2020-01-012020-12-3100018498532021-03-042021-03-0400018498532021-07-202021-07-200001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2021-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:FinancialCurrentAssetsMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:EmployeeBenefitsMember2021-12-310001849853stvn:ReserveOfRemeasurementsOfDefinedBenefitPlansAndAgentTerminationPlanMember2021-12-310001849853stvn:NotesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-12-310001849853ifrs-full:OtherIntangibleAssetsMemberstvn:AmortizationMember2021-01-012021-12-310001849853stvn:WincklerCoLtdMember2021-12-310001849853ifrs-full:WeightedAverageCostOfCapitalMeasurementInputMemberstvn:DrugContainmentSystemsMember2021-01-012021-12-310001849853stvn:LeasesMember2021-12-310001849853stvn:DerivativesFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:PropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2019-12-310001849853stvn:MJBConsultantsLLCMember2019-01-012019-12-310001849853ifrs-full:FloatingInterestRateMemberifrs-full:InterestRateRiskMember2021-12-310001849853ifrs-full:ActuarialAssumptionOfDiscountRatesMember2020-12-310001849853ifrs-full:TopOfRangeMember2021-01-012021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:MachineryMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:DepreciationAndAmortizationMember2019-01-012019-12-310001849853srt:AsiaPacificMember2019-01-012019-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberstvn:AmortizationMember2020-01-012020-12-310001849853stvn:MedicalGlassASMemberstvn:IndirectControlMember2021-01-012021-12-310001849853stvn:EngineeringSegmentMembersrt:SouthAmericaMember2019-01-012019-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:DerivativesFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:TradePayablesMember2020-12-310001849853stvn:TrattamentoFineRapportoMember2021-12-310001849853ifrs-full:WarrantyProvisionMember2020-12-310001849853stvn:ExchangeRateSensitivityOneMemberstvn:ForwardForeignExchangeContractsMember2021-01-012021-12-310001849853stvn:DueOn2026Memberstvn:BankLoansMember2020-01-012020-12-310001849853ifrs-full:PropertyPlantAndEquipmentMember2020-12-3100018498532020-01-012020-12-310001849853stvn:SecuredGuaranteesMember2020-12-310001849853stvn:AmortizationMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2020-01-012020-12-310001849853stvn:BankOverdraftMember2021-12-310001849853ifrs-full:InterestRateRiskMemberstvn:FinancialLiabilitiesDueToOtherLendersMember2021-01-012021-12-310001849853stvn:NotesMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:OtherCurrentFinancialAssetsMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:JPY2021-12-310001849853country:MX2020-01-012020-12-310001849853ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2020-12-310001849853stvn:HoldingSegmentMemberifrs-full:TopOfRangeMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-01-012021-12-310001849853country:JP2021-01-012021-12-310001849853stvn:NotesMemberstvn:DueOn2028Member2021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMember2021-01-012021-12-310001849853ifrs-full:Level3OfFairValueHierarchyMemberstvn:EquityInvestmentsOthersMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2019-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2020-01-012020-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMemberstvn:OtherLiabilityMember2021-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMemberstvn:OtherFinancialLiabilitiesMember2021-12-310001849853ifrs-full:PropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2020-12-310001849853stvn:EngineeringSegmentMember2020-01-012020-12-310001849853stvn:BankLoansMemberstvn:DueOn2025Member2020-12-310001849853stvn:SVMAutomatikASMember2021-10-072021-10-070001849853ifrs-full:Level1OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853country:IT2021-01-012021-12-310001849853ifrs-full:FloatingInterestRateMemberstvn:BankOverdraftMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:CustomerMemberstvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMember2019-01-012019-12-310001849853country:DE2020-12-310001849853stvn:SocietaAgricolaStellaSRLMember2020-01-012020-12-310001849853stvn:TaxPayablesMember2020-12-310001849853stvn:FinancialLiabilitiesDueToRelatedPartiesMemberifrs-full:InterestRateRiskMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IndustrialEquipmentMember2021-12-310001849853stvn:SpamiSRLMemberstvn:DirectControlMember2020-01-012020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:NorthAmericaMember2020-01-012020-12-310001849853stvn:InVitroDiagnosticConsumablesDrugDeliverySystemsMember2021-12-310001849853stvn:EngineeringSegmentMember2019-01-012019-12-310001849853ifrs-full:NotLaterThanOneYearMember2020-01-012020-12-310001849853stvn:StevanatoGroupInternationalSMemberstvn:DirectControlMember2021-01-012021-12-310001849853stvn:RestrictedStockGrantPlan20212027Member2021-12-310001849853country:BR2020-12-310001849853stvn:FinancialCurrentAssetsMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:IndirectControlMemberstvn:SVMAutomatikASMember2020-01-012020-12-310001849853stvn:DerivativeInstrumentMember2020-12-310001849853ifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853country:MX2020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:EuropeMiddleEastAndAfricaMember2020-01-012020-12-310001849853stvn:OtherKeyManagementMember2021-01-012021-12-310001849853ifrs-full:ReserveOfCashFlowHedgesMember2020-12-310001849853stvn:EngineeringSegmentMembersrt:SouthAmericaMember2021-01-012021-12-310001849853stvn:EngineeringSegmentMemberstvn:RevenuesFromEngineeringMember2019-01-012019-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310001849853stvn:CustomerMember2020-01-012020-12-310001849853stvn:CurrentFinancialLiabilitiesMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2021-01-012021-12-310001849853stvn:ProvisionForAgentsAndDirectorsSeveranceIndemnityMember2021-01-012021-12-310001849853ifrs-full:NoncontrollingInterestsMember2018-12-310001849853stvn:WorkInProgressMember2021-12-310001849853stvn:EngineeringSegmentMembersrt:NorthAmericaMember2020-01-012020-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:LeaseLiabilityMember2021-12-310001849853ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:OtherTangibleAssetsMember2021-01-012021-12-310001849853stvn:NordeaBankOnBehalfOfSVMAutomatikASMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:OtherTangibleAssetsMember2019-12-310001849853stvn:CashSettledAwardsPeriodFiveMemberifrs-full:SellingGeneralAndAdministrativeExpenseMember2021-01-012021-12-310001849853stvn:EngineeringSegmentMember2021-01-012021-12-310001849853ifrs-full:PropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853stvn:GeneralAndAdministrativeExpensesMember2021-01-012021-12-310001849853country:SK2021-12-310001849853ifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853country:SK2020-12-310001849853stvn:HoldingSegmentMemberstvn:IndustrialAndCommercialEquipmentMember2021-01-012021-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:AssociatesMember2019-01-012019-12-310001849853ifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:AmortizationMemberstvn:IndustrialPatentsAndIntellectualPropertyRightsMember2021-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMember2021-01-012021-12-310001849853stvn:CurrentFinancialLiabilitiesMembercurrency:CHFstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2020-12-310001849853stvn:BankOverdraftMemberifrs-full:InterestRateRiskMember2020-01-012020-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberstvn:DepreciationAndImpairmentMember2020-01-012020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:TopOfRangeMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-01-012021-12-310001849853ifrs-full:TreasurySharesMember2021-01-012021-12-310001849853stvn:ReserveOfRemeasurementsOfDefinedBenefitPlansAndAgentTerminationPlanMember2020-12-310001849853ifrs-full:CapitalisedDevelopmentExpenditureMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:PlantAndMachineryMember2020-12-310001849853stvn:SwissfillonAGMember2020-01-012020-12-310001849853stvn:ExchangeRateSensitivityUsDollarMemberstvn:ForwardForeignExchangeContractsMember2021-01-012021-12-310001849853ifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310001849853ifrs-full:SharePremiumMember2021-01-012021-12-310001849853stvn:RevaluationsOfInvestmentPropertiesToFairValueMember2020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberstvn:IndustrialEquipmentMember2019-12-310001849853stvn:EFKHEjendommeApSMember2021-01-012021-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:TaxPayablesMember2020-12-310001849853stvn:IndustrialEquipmentMember2021-12-310001849853stvn:CashSettledAwardsMember2021-12-310001849853stvn:BorrowingsFromBanksMember2020-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2020-12-310001849853ifrs-full:AssociatesMember2021-01-012021-12-310001849853stvn:HoldingSegmentMemberifrs-full:BuildingsMember2021-01-012021-12-310001849853stvn:CashSettledAwardsPeriodOneMemberstvn:CashSettledAwardsMember2021-01-012021-12-310001849853stvn:AmortizationMember2021-12-310001849853stvn:NotesMemberifrs-full:InterestRateRiskMemberifrs-full:FixedInterestRateMember2020-12-310001849853stvn:FinancialCurrentAssetsMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:OtherContainmentAndDeliverySolutionsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2020-01-012020-12-310001849853ifrs-full:GoodsOrServicesTransferredOverTimeMemberstvn:InVitroDiagnosticBusinessMember2021-01-012021-12-310001849853ifrs-full:EliminationOfIntersegmentAmountsMember2019-01-012019-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMemberstvn:EmployeeBenefitsMember2020-12-310001849853ifrs-full:UnusedTaxLossesMember2020-12-310001849853ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2021-12-310001849853ifrs-full:AssociatesMember2020-01-012020-12-310001849853country:JP2019-01-012019-12-310001849853stvn:PlantAndMachineryMemberstvn:DepreciationAndImpairmentMember2020-12-310001849853stvn:NuovaOmpiSRLMember2020-01-012020-12-310001849853stvn:InVitroDiagnosticConsumablesDrugDeliverySystemsMember2021-01-012021-12-310001849853country:US2021-12-310001849853stvn:InterestRateSensitivityThreeMember2020-01-012020-12-310001849853ifrs-full:IssuedCapitalMember2018-12-310001849853ifrs-full:PurchasedCallOptionsMemberstvn:CashSettledAwardsPeriodOneMember2021-03-042021-06-030001849853stvn:NotesMemberstvn:DueFromYearOneToYearEightMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-01-012020-12-310001849853ifrs-full:PropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2021-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:BorrowingsFromBanksMember2021-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMember2021-12-310001849853ifrs-full:FloatingInterestRateMemberstvn:BankOverdraftMemberifrs-full:InterestRateRiskMember2021-12-310001849853stvn:StevanatoMarcoMember2019-01-012019-12-310001849853ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001849853ifrs-full:IssuedCapitalMember2021-12-310001849853stvn:BankLoansMemberstvn:DueOn2023Member2021-12-310001849853stvn:ResearchAndDevelopmentExpensesMember2020-01-012020-12-310001849853stvn:PlantAndMachineryMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853ifrs-full:EquityAttributableToOwnersOfParentMember2021-01-012021-12-310001849853country:DK2020-01-012020-12-310001849853stvn:AmortizationMember2020-01-012020-12-310001849853stvn:DueOn2021Memberstvn:BankLoansMember2020-12-310001849853stvn:FinancialLiabilitiesDueToRelatedPartiesMemberifrs-full:InterestRateRiskMemberifrs-full:FixedInterestRateMember2020-12-310001849853ifrs-full:ReserveOfCashFlowHedgesMember2021-01-012021-12-310001849853stvn:IndustrialEquipmentMember2020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMember2020-01-012020-12-310001849853stvn:StudioLegaleSpinazziAzzaritaTroiMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2020-12-310001849853stvn:OtherCostsAndIncomesMember2021-01-012021-12-310001849853stvn:EquityInvestmentsOthersMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853country:CH2021-12-310001849853ifrs-full:RetainedEarningsMember2021-01-012021-12-310001849853stvn:RestrictedStockGrantPlan20212027Member2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:AssetsUnderConstructionAndAdvancesMember2021-12-310001849853stvn:ForwardForeignExchangeContractsMemberstvn:ExchangeRateSensitivityEuroOneMember2020-01-012020-12-310001849853stvn:BankLoansMemberifrs-full:InterestRateRiskMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:AssetsUnderConstructionAndAdvancesMember2020-01-012020-12-310001849853stvn:BeneficioPorRetiroTerminacionMember2021-12-310001849853stvn:ExchangeRateSensitivityMexicanPesosMemberstvn:ForwardForeignExchangeContractsMember2021-01-012021-12-310001849853stvn:OmpiPharmaPackagingTechCoLtdMembercountry:CN2020-12-310001849853stvn:CustomerMember2019-01-012019-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMemberstvn:InterSegmentMember2020-01-012020-12-310001849853ifrs-full:NoncontrollingInterestsMember2021-01-012021-12-310001849853stvn:DepreciationAndImpairmentMember2020-12-310001849853stvn:TrattamentoFineRapportoMember2020-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2020-01-012020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:NorthAmericaMember2021-01-012021-12-310001849853stvn:LeasesMember2020-12-310001849853ifrs-full:ForwardContractMember2020-12-310001849853ifrs-full:MaterialReconcilingItemsMember2019-01-012019-12-310001849853country:CH2019-01-012019-12-310001849853stvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2021-12-310001849853stvn:IncreaseDecreaseDueToApplicationOfIFRSNineMember2020-12-310001849853ifrs-full:LandAndBuildingsMemberstvn:DepreciationAndImpairmentMember2020-01-012020-12-310001849853ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2019-01-012019-12-310001849853ifrs-full:NoncontrollingInterestsMember2020-01-012020-12-310001849853stvn:BankLoansMemberstvn:DueOn2023Member2021-01-012021-12-310001849853ifrs-full:EquityAttributableToOwnersOfParentMember2019-12-3100018498532020-04-162020-04-160001849853ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2018-12-310001849853stvn:CustomerMember2021-01-012021-12-310001849853stvn:AmortizationMember2019-12-310001849853stvn:ExpectedCreditLossesMember2020-01-012020-12-310001849853stvn:OtherLiabilityMember2020-12-310001849853ifrs-full:OtherIntangibleAssetsMemberstvn:AmortizationMember2019-12-310001849853stvn:AmortizationMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2021-01-012021-12-310001849853stvn:InterestRateSensitivityThreeMember2021-01-012021-12-310001849853stvn:TrattamentoFineRapportoMember2020-01-012020-12-310001849853ifrs-full:IssuedCapitalMember2021-01-012021-12-310001849853stvn:BeneficioPorRetiroTerminacionMember2020-12-310001849853country:IT2020-12-310001849853ifrs-full:Level3OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:OtherNonCurrentFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:LongTermIncentivePlanPeriodTwoMemberstvn:LongTermIncentivePlanMember2020-01-012020-12-310001849853stvn:FedericiWilliamMember2021-01-012021-12-310001849853country:MX2019-12-310001849853stvn:DueFromYearOneToYearSevenMemberstvn:BankLoansMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2020-01-012020-12-310001849853ifrs-full:LandAndBuildingsMemberstvn:DepreciationAndImpairmentMember2020-12-310001849853stvn:PayablesForSubsidiaryAcquisitionMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:IntangibleFixedAssetsInProcessAndAdvancesMember2021-01-012021-12-310001849853stvn:InVitroDiagnosticConsumablesDrugDeliverySystemsMemberifrs-full:WeightedAverageCostOfCapitalMeasurementInputMember2021-01-012021-12-310001849853stvn:OtherIntangiblesAssetsMember2021-12-310001849853country:BR2019-12-310001849853stvn:ProvisionForAgentsAndDirectorsSeveranceIndemnityMember2019-12-310001849853ifrs-full:TreasurySharesMember2021-06-030001849853stvn:BaldaMedicalGmbhMemberstvn:DirectControlMember2020-01-012020-12-310001849853stvn:CashAndCashEquivalentMemberifrs-full:Level1OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2019-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMemberstvn:OtherLiabilityMember2020-12-310001849853stvn:DerivativeInstrumentMember2021-12-310001849853stvn:DueOn2021Memberstvn:BankLoansMember2020-01-012020-12-310001849853stvn:JubileeBenefitsMember2020-12-310001849853ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:PiovesanBarbaraMember2021-01-012021-12-310001849853stvn:OverdueWithin90DaysMember2021-12-310001849853ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2020-01-012020-12-310001849853ifrs-full:LegalProceedingsProvisionMember2021-12-310001849853ifrs-full:ReserveOfCashFlowHedgesMember2021-12-310001849853stvn:BeneficioPorRetiroTerminacionMember2021-01-012021-12-310001849853stvn:EngineeringSystemsMember2020-12-310001849853stvn:StudioLegaleSpinazziAzzaritaTroiMember2021-01-012021-12-310001849853stvn:DepreciationAndAmortizationMember2020-01-012020-12-310001849853stvn:DueOn2024Memberstvn:BankLoansMember2021-01-012021-12-310001849853stvn:SVMAutomatikASMember2021-10-070001849853stvn:DueOn2022Memberstvn:OverDraftsMember2021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-12-310001849853stvn:TaxPayablesMember2021-12-310001849853ifrs-full:WarrantyProvisionMember2019-12-310001849853ifrs-full:LegalProceedingsProvisionMember2020-12-310001849853stvn:CashSettledAwardsPeriodTwoMemberstvn:CashSettledAwardsMember2019-12-310001849853stvn:EngineeringSegmentMemberifrs-full:TopOfRangeMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-01-012021-12-310001849853ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2021-12-310001849853stvn:PGIMIncMember2021-01-012021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BuildingsMember2021-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberifrs-full:GrossCarryingAmountMember2020-12-310001849853stvn:IncogBiopharmaServicesIncMember2021-01-012021-12-310001849853ifrs-full:IssuedCapitalMember2019-12-310001849853stvn:LongTermIncentivePlanMember2021-12-310001849853ifrs-full:TreasurySharesMember2019-12-310001849853stvn:NotesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-01-012021-12-310001849853country:CN2020-01-012020-12-310001849853ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001849853stvn:OtherIntangiblesAssetsMember2020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:AsiaPacificMember2021-01-012021-12-310001849853stvn:OmpiOfJapanCoLtdMember2020-12-310001849853stvn:DirectControlMemberstvn:OmpiNASDeRLDeCVMember2021-01-012021-12-310001849853stvn:CurrentFinancialLiabilitiesMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:JPY2020-12-310001849853ifrs-full:TreasurySharesMember2018-12-310001849853ifrs-full:SharePremiumMember2021-12-310001849853stvn:LeaseLiabilityMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-12-310001849853stvn:BorrowingsFromBanksMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001849853stvn:OtherCostsAndIncomesMember2020-01-012020-12-310001849853stvn:CustomerMemberifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:AssetsUnderConstructionAndAdvancesMember2020-12-310001849853stvn:CashSettledAwardsPeriodOneMemberstvn:CashSettledAwardsMember2020-12-310001849853stvn:SEHoldingsCoLtdMember2021-12-310001849853stvn:AmortizationMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2021-12-310001849853stvn:CustomerMemberifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2021-01-012021-12-310001849853stvn:EngineeringSystemsMember2021-01-012021-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberstvn:DepreciationAndImpairmentMember2021-01-012021-12-310001849853stvn:ActuarialAssumptionOfTurnoverRatesMember2020-12-310001849853stvn:IndirectControlMemberstvn:OmpiPharmPackingTechnCoLtdMember2020-01-012020-12-310001849853stvn:SeverancePaymentSlovakiaMember2021-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:OtherNonCurrentFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:BuildingsMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853country:JP2020-01-012020-12-310001849853stvn:DueOn2024Memberstvn:BankLoansMember2021-12-310001849853stvn:OtherTangibleAssetsMember2021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMember2021-01-012021-12-310001849853ifrs-full:PropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853stvn:DividendsMember2020-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853stvn:CurrentFinancialLiabilitiesMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMember2020-12-310001849853stvn:TrattamentoFineRapportoMember2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310001849853stvn:DueOn2027Memberstvn:BankLoansMember2020-01-012020-12-310001849853stvn:BankLoansMemberstvn:DueOn2023Member2020-12-310001849853stvn:CreditInstitutionsAndInsuranceCompaniesMember2020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:PropertyPlantAndEquipmentMember2020-01-012020-12-310001849853ifrs-full:EquityAttributableToOwnersOfParentMember2020-12-310001849853ifrs-full:GrossCarryingAmountMember2019-12-310001849853country:BR2019-01-012019-12-310001849853stvn:SeverancePaymentSlovakiaMember2020-01-012020-12-310001849853stvn:JubileeBenefitsMember2021-01-012021-12-310001849853ifrs-full:LandAndBuildingsMember2020-12-310001849853stvn:BankLoansMemberstvn:DueOn2025Member2021-12-310001849853srt:SouthAmericaMember2021-01-012021-12-310001849853stvn:OtherTangibleAssetsMemberstvn:DepreciationAndImpairmentMember2019-12-310001849853stvn:BorrowingsFromBanksMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-12-310001849853stvn:NuovaOmpiSRLMember2019-01-012019-12-310001849853country:BR2021-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberifrs-full:GrossCarryingAmountMember2021-12-310001849853ifrs-full:LandAndBuildingsMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:OtherTangibleAssetsMember2021-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember2021-01-012021-12-310001849853stvn:CashSettledAwardsMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IndustrialEquipmentMember2021-01-012021-12-310001849853ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2021-01-012021-12-310001849853ifrs-full:OrdinarySharesMember2021-01-012021-12-310001849853stvn:PlantAndMachineryMemberifrs-full:GrossCarryingAmountMember2021-12-310001849853ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2021-01-012021-12-310001849853stvn:OmpiPharmaPackagingTechCoLtdAndNuovaOmpiSRLMember2021-01-012021-12-310001849853stvn:ProvisionsMember2021-12-310001849853stvn:CashSettledAwardsMember2020-01-012020-12-310001849853stvn:ExecutivesMember2020-01-012020-12-310001849853country:CN2020-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberstvn:AmortizationMember2020-01-012020-12-310001849853ifrs-full:LandAndBuildingsMemberstvn:DepreciationAndImpairmentMember2019-12-310001849853stvn:DueOn2021Memberstvn:OverDraftsMember2020-01-012020-12-310001849853ifrs-full:MaterialReconcilingItemsMember2020-12-310001849853stvn:OmpiDoBrasilICDeEmFarLtdaMemberstvn:DirectControlMember2021-01-012021-12-310001849853stvn:SeniorNotesSeriesADueApril162028Member2020-04-160001849853stvn:WincklerCoLtdMember2020-01-012020-12-310001849853country:DK2020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:HighValueSolutionsMember2020-01-012020-12-310001849853stvn:DepreciationAndImpairmentMember2019-12-310001849853country:US2020-12-310001849853stvn:SEHoldingsCoLtdMember2020-12-310001849853stvn:OmpiPharmaPackagingTechCoLtdMember2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2021-12-310001849853stvn:DepreciationAndImpairmentMember2021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2021-01-012021-12-310001849853stvn:PGIMIncMember2021-12-310001849853ifrs-full:ProvisionForDecommissioningRestorationAndRehabilitationCostsMember2021-12-310001849853stvn:DerivativesFinancialLiabilitiesMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:ReserveOfRemeasurementsOfDefinedBenefitPlansAndAgentTerminationPlanMember2019-01-012019-12-310001849853stvn:HighValueSolutionsMember2021-01-012021-12-310001849853stvn:InterestRateSensitivityTwoMember2020-01-012020-12-310001849853stvn:VehiclesAndOtherEquipmentMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:HighValueSolutionsMember2021-01-012021-12-310001849853ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2021-01-012021-12-310001849853ifrs-full:FloatingInterestRateMemberstvn:BankLoansMemberifrs-full:InterestRateRiskMember2020-12-310001849853ifrs-full:FixedInterestRateMemberifrs-full:InterestRateRiskMember2021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMemberstvn:InterSegmentMember2021-01-012021-12-310001849853stvn:MJBConsultantsLLCMember2020-01-012020-12-310001849853ifrs-full:InterestRateRiskMemberstvn:InterestRateSwapIRSMember2020-12-310001849853stvn:ManagersMember2020-01-012020-12-310001849853ifrs-full:InterestRateRiskMemberstvn:FinancialPayablesForShareAcquisitionMember2020-12-310001849853ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-12-310001849853ifrs-full:CostOfSalesMember2019-01-012019-12-310001849853stvn:AmortizationMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2019-12-310001849853stvn:OtherEffectsMember2020-12-310001849853srt:NorthAmericaMember2020-12-310001849853ifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2020-12-310001849853stvn:SocietaAgricolaStellaSRLMember2021-12-310001849853stvn:CTSStudioAsMember2021-12-310001849853stvn:SellingAndMarketingExpensesMember2020-01-012020-12-310001849853stvn:IndirectControlMemberstvn:BaldaPrecisionIncMember2020-01-012020-12-310001849853stvn:TradePayablesMember2020-12-310001849853stvn:IndirectControlMemberstvn:OmpiNASDeRLDeCVMember2021-01-012021-12-310001849853stvn:OtherCurrentFinancialAssetsMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:JPY2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:HighValueSolutionsMember2019-01-012019-12-310001849853stvn:InterestRateSensitivityTwoMember2021-01-012021-12-310001849853ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853stvn:ExpectedCreditLossesOfDebtFinancialAssetsMember2021-12-310001849853ifrs-full:InterestRateRiskMember2020-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberifrs-full:GrossCarryingAmountMember2019-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2021-01-012021-12-310001849853stvn:StevanatoGroupNASDeRLDeCVMemberstvn:IndirectControlMember2020-01-012020-12-310001849853stvn:BankLoansMemberstvn:DueOn2022Member2020-12-310001849853ifrs-full:NoncontrollingInterestsMember2020-12-310001849853stvn:ManagersMember2019-01-012019-12-310001849853ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember2020-01-012020-12-310001849853stvn:EngineeringSegmentMembersrt:NorthAmericaMember2019-01-012019-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2021-01-012021-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:IndirectControlMemberstvn:BaldaCBrewerIncMember2021-01-012021-12-310001849853stvn:UnsecuredGuaranteesMember2021-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMember2020-12-310001849853stvn:RevenuesFromEngineeringMember2021-01-012021-12-310001849853stvn:DepreciationAndImpairmentMember2020-01-012020-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMemberstvn:InterSegmentMember2021-01-012021-12-310001849853stvn:PlantAndMachineryMemberstvn:DepreciationAndImpairmentMember2021-12-310001849853stvn:PlantAndMachineryMemberifrs-full:GrossCarryingAmountMember2019-12-310001849853stvn:NotesMemberifrs-full:InterestRateRiskMemberifrs-full:FixedInterestRateMember2021-12-310001849853stvn:OmpiOfJapanCoLtdMember2021-12-310001849853ifrs-full:OtherReservesMember2021-01-202021-01-200001849853stvn:DrugContainmentSystemsMember2021-01-012021-12-310001849853stvn:LeaseLiabilityMember2021-12-310001849853stvn:HoldingSegmentMemberifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:SellingAndMarketingExpensesMember2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:NorthAmericaMember2019-01-012019-12-310001849853stvn:BeneficioPorRetiroTerminacionMember2020-01-012020-12-310001849853ifrs-full:LandAndBuildingsMemberstvn:DepreciationAndImpairmentMember2021-01-012021-12-310001849853stvn:NotesMemberifrs-full:InterestRateRiskMember2020-01-012020-12-310001849853ifrs-full:NotLaterThanOneYearMember2021-12-310001849853ifrs-full:InterestRateRiskMemberstvn:InterestRateSwapIRSMember2021-12-310001849853stvn:LongTermIncentivePlanMember2020-01-012020-12-310001849853stvn:IndirectControlMemberstvn:OmpiNASDeRLDeCVMember2020-01-012020-12-310001849853stvn:OtherTangibleAssetsMemberstvn:DepreciationAndImpairmentMember2021-01-012021-12-310001849853country:US2020-01-012020-12-310001849853ifrs-full:NoncontrollingInterestsMember2021-12-310001849853stvn:PlantAndMachineryMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853stvn:EuropeMiddleEastAndAfricaMember2020-01-012020-12-310001849853stvn:LongTermIncentivePlanMember2020-12-310001849853stvn:ReserveOfRemeasurementsOfDefinedBenefitPlansAndAgentTerminationPlanMember2018-12-310001849853ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2019-01-012019-12-310001849853stvn:LaterThanSixYearsMember2020-01-012020-12-310001849853stvn:NotesMemberifrs-full:InterestRateRiskMember2021-01-012021-12-310001849853stvn:OtherContainmentAndDeliverySolutionsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2021-01-012021-12-310001849853ifrs-full:SellingGeneralAndAdministrativeExpenseMember2020-01-012020-12-310001849853stvn:ProgenitorCapitalPartnersLlcMember2019-01-012019-12-310001849853ifrs-full:FloatingInterestRateMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:EuropeMiddleEastAndAfricaMember2020-12-310001849853stvn:NuovaOmpiSRLMember2021-01-012021-12-310001849853stvn:OtherNonCurrentFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2020-12-310001849853srt:SouthAmericaMember2021-12-310001849853stvn:SEHoldingsCoLtdMember2021-01-012021-12-310001849853stvn:LongTermIncentivePlanPeriodTwoMemberstvn:LongTermIncentivePlanMember2021-01-012021-12-310001849853stvn:OtherTangibleAssetsMemberstvn:DepreciationAndImpairmentMember2020-01-012020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2020-01-012020-12-310001849853ifrs-full:InterestRateRiskMemberstvn:FinancialPayablesForShareAcquisitionMember2021-01-012021-12-310001849853stvn:CurrentFinancialLiabilitiesMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:AsiaPacificMember2019-01-012019-12-310001849853ifrs-full:WarrantyProvisionMember2021-12-310001849853stvn:ProgenitorCapitalPartnersLlcMember2020-01-012020-12-310001849853ifrs-full:RetainedEarningsMember2020-12-310001849853stvn:OmpiDoBrasilICDeEmFarLtdaMemberstvn:IndirectControlMember2020-01-012020-12-310001849853ifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2021-12-310001849853stvn:OmpiPharmaPackagingTechCoLtdMembercountry:CN2020-01-012020-12-310001849853stvn:OtherEffectsMember2021-12-310001849853stvn:IncreaseDecreaseDueToApplicationOfIFRSNineMember2021-12-310001849853stvn:IndirectControlMemberstvn:BaldaPrecisionIncMember2021-01-012021-12-310001849853country:US2019-12-310001849853ifrs-full:ActuarialAssumptionOfExpectedRatesOfInflationMember2020-12-310001849853stvn:CurrentFinancialLiabilitiesMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMember2021-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001849853ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember2020-01-012020-12-310001849853stvn:LaterThanFiveYearsAndNotLaterThanSixYearsMember2021-01-012021-12-310001849853ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2020-12-310001849853stvn:SeverancePaymentSlovakiaMember2021-01-012021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:TopOfRangeMemberifrs-full:BuildingsMember2021-01-012021-12-310001849853stvn:OtherCurrentFinancialAssetsMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:USDstvn:CarryingValueMember2020-12-310001849853stvn:OverdueBetween181And365DaysMember2021-12-310001849853stvn:BankLoansMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2021-01-012021-12-310001849853stvn:AssetsUnderConstructionAndAdvancesMember2021-12-310001849853stvn:AmortizationMemberstvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2019-12-310001849853country:DK2019-12-310001849853stvn:DueOn2024Memberstvn:BankLoansMember2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:OtherTangibleAssetsMember2020-12-310001849853stvn:CashSettledAwardsPeriodOneMemberstvn:CashSettledAwardsMember2019-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberstvn:DepreciationAndImpairmentMember2019-12-310001849853stvn:EngineeringSystemAndInVitroDiagnosticBusinessMember2020-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:BankOverdraftMember2020-12-310001849853stvn:ExchangeRateSensitivityEuroMemberstvn:ForwardForeignExchangeContractsMember2021-01-012021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2019-12-310001849853stvn:NordeaBankOnBehalfOfSVMInnoscanASMember2021-01-012021-12-310001849853stvn:FinancialLiabilitiesDueToRelatedPartiesMemberifrs-full:InterestRateRiskMember2021-01-012021-12-310001849853stvn:OtherContainmentAndDeliverySolutionsMember2019-01-012019-12-310001849853stvn:StartUpCostsIPOSGSpaMember2021-12-310001849853ifrs-full:BuildingsMember2020-12-310001849853ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember2020-01-012020-12-310001849853stvn:WincklerCoLtdMember2020-12-310001849853stvn:BankLoansMemberifrs-full:InterestRateRiskMemberstvn:InterestRateSwapIRSMember2021-12-310001849853ifrs-full:SellingGeneralAndAdministrativeExpenseMember2021-01-012021-12-310001849853stvn:CashSettledAwardsMember2019-12-310001849853stvn:EmployeesMember2019-01-012019-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853stvn:TrattamentoFineRapportoMember2019-12-310001849853stvn:FinancialLiabilitiesDueToRelatedPartiesMemberifrs-full:InterestRateRiskMember2020-01-012020-12-310001849853stvn:SaleOfResidentialFlatMember2019-01-012019-12-310001849853ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2019-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberstvn:IndustrialEquipmentMember2021-12-310001849853stvn:AmortizationMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2021-01-012021-12-310001849853stvn:InvestmentInBiologixPartnersLPMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2020-01-012020-12-310001849853stvn:CustomerMemberifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2021-01-012021-12-310001849853stvn:SFEMItaliaSRLMember2020-01-012020-12-310001849853country:CN2019-12-310001849853stvn:DueOn2026Memberstvn:BankLoansMember2021-01-012021-12-310001849853stvn:RevenuesFromEngineeringMember2020-01-012020-12-310001849853country:US2021-01-012021-12-310001849853stvn:InterestRateSensitivityOneMember2021-01-012021-12-310001849853stvn:NotesMemberifrs-full:InterestRateRiskMember2021-12-310001849853stvn:OmpiOfJapanCoLtdMember2021-01-012021-12-310001849853stvn:ProvisionForAgentsAndDirectorsSeveranceIndemnityMember2020-01-012020-12-310001849853stvn:SEHoldingsCoLtdMember2019-01-012019-12-310001849853country:DE2021-12-310001849853stvn:BankLoansMemberifrs-full:InterestRateRiskMemberstvn:InterestRateSwapIRSMember2020-12-310001849853ifrs-full:OtherIntangibleAssetsMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:OmpiDoBrasilICDeEmFarLtdaMemberstvn:IndirectControlMember2021-01-012021-12-310001849853stvn:OtherCostsAndIncomesMember2019-01-012019-12-310001849853ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-12-310001849853srt:NorthAmericaMember2020-01-012020-12-310001849853stvn:CashSettledAwardsPeriodTwoMemberstvn:CashSettledAwardsMember2020-12-310001849853stvn:NotesMemberifrs-full:LaterThanFiveYearsMember2021-12-310001849853srt:SouthAmericaMember2020-01-012020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:SouthAmericaMember2019-01-012019-12-310001849853ifrs-full:PropertyPlantAndEquipmentMember2021-12-310001849853stvn:NotesMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMemberstvn:DueFromYearOneToYearEightMember2020-12-310001849853stvn:PersonnelExpensesMember2021-01-012021-12-310001849853stvn:RevenuesFromEngineeringMember2019-01-012019-12-310001849853stvn:CashSettledAwardsPeriodOneMemberstvn:CashSettledAwardsMember2020-01-012020-12-310001849853stvn:CurrentFinancialLiabilitiesMembercurrency:CHFstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2020-01-012020-12-310001849853stvn:EngineeringSystemAndInVitroDiagnosticBusinessMember2021-12-310001849853stvn:MedirioSAMemberstvn:IndirectControlMember2020-01-012020-12-310001849853stvn:ProgenitorCapitalPartnersLlcMember2021-01-012021-12-310001849853country:BR2021-01-012021-12-310001849853ifrs-full:NoncontrollingInterestsMember2019-12-310001849853stvn:TradePayablesMember2021-12-310001849853stvn:DueOn2027Memberstvn:BankLoansMember2020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMember2019-01-012019-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2021-12-310001849853ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2019-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMember2021-12-310001849853stvn:BankOverdraftMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:TangibleAssetsMember2020-12-310001849853stvn:OverdueBeyond365DaysMember2021-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2021-01-012021-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:ForwardForeignExchangeContractsMemberstvn:ExchangeRateSensitivityMember2020-01-012020-12-310001849853stvn:EngineeringSegmentMembersrt:NorthAmericaMember2021-01-012021-12-310001849853ifrs-full:InterestRateRiskMember2021-12-310001849853country:BR2020-01-012020-12-310001849853stvn:DrugContainmentSystemsMember2021-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberifrs-full:GrossCarryingAmountMember2020-12-310001849853stvn:ExpectedCreditLossesMember2021-01-012021-12-310001849853stvn:ExpectedCreditLossesOfDebtFinancialAssetsMember2020-12-310001849853stvn:BankLoansMember2020-12-310001849853stvn:BankLoansMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:JubileeBenefitsMember2020-01-012020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2020-01-012020-12-310001849853stvn:NotesMemberstvn:DueOn2028Member2020-12-310001849853stvn:CurrentFinancialLiabilitiesMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2020-01-012020-12-310001849853stvn:StudioLegaleSpinazziAzzaritaTroiMember2019-01-012019-12-310001849853stvn:BankLoansMember2021-12-310001849853country:JP2021-12-310001849853stvn:ExchangeRateSensitivityEuroMemberstvn:ForwardForeignExchangeContractsMember2020-01-012020-12-310001849853stvn:FondazioneStevanatoMember2019-01-012019-12-310001849853stvn:AmortizationMember2020-12-310001849853stvn:EngineeringSegmentMemberstvn:IndustrialAndCommercialEquipmentMember2021-01-012021-12-310001849853stvn:InterestRateSwapInCashFlowHedgesMember2020-12-310001849853stvn:LeaseLiabilityMemberifrs-full:LaterThanFiveYearsMember2021-12-310001849853stvn:SwissfillonAGMember2021-12-310001849853stvn:PayablesForSubsidiaryAcquisitionMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853country:CN2021-01-012021-12-310001849853ifrs-full:FixedInterestRateMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:CashSettledAwardsMember2020-12-310001849853stvn:OtherContainmentAndDeliverySolutionsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2019-01-012019-12-310001849853stvn:DueOn2027Memberstvn:BankLoansMember2021-01-012021-12-310001849853stvn:AmortizationMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2021-12-310001849853stvn:DueOn2026Memberstvn:BankLoansMember2020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2019-01-012019-12-310001849853srt:NorthAmericaMember2019-01-012019-12-310001849853dei:BusinessContactMember2021-01-012021-12-310001849853ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2020-01-012020-12-310001849853ifrs-full:WrittenPutOptionsMemberstvn:SVMAutomatikASMember2020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-01-012021-12-310001849853stvn:DueOn2026Memberstvn:BankLoansMember2021-12-310001849853country:DK2019-01-012019-12-310001849853ifrs-full:GrossCarryingAmountMember2021-12-310001849853stvn:ReserveOfRemeasurementsOfDefinedBenefitPlansAndAgentTerminationPlanMember2019-12-310001849853stvn:OtherCurrentFinancialAssetsMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMemberstvn:CarryingValueMembercurrency:JPY2021-12-310001849853ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:TaxPayablesMember2021-12-3100018498532020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMembersrt:SouthAmericaMember2021-01-012021-12-310001849853country:JP2019-12-310001849853ifrs-full:Level3OfFairValueHierarchyMemberstvn:EquityInvestmentsOthersMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853ifrs-full:TopOfRangeMemberstvn:VehiclesAndOtherEquipmentMember2021-01-012021-12-310001849853stvn:DCSAndIVDDDSMember2021-12-310001849853stvn:DrugContainmentSystemsMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853ifrs-full:NotLaterThanOneYearMember2021-01-012021-12-310001849853ifrs-full:ReserveOfCashFlowHedgesMember2019-12-310001849853stvn:DepreciationAndImpairmentMember2021-01-012021-12-310001849853stvn:CustomerMemberifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2019-01-012019-12-310001849853stvn:AmortizationMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2020-01-012020-12-310001849853stvn:ForwardForeignExchangeContractsMemberstvn:ExchangeRateSensitivityMember2021-01-012021-12-310001849853ifrs-full:LaterThanFiveYearsMember2020-12-310001849853stvn:IndustrialPatentsAndIntellectualPropertyRightsMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853stvn:LongTermIncentivesMember2020-12-310001849853ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2020-12-310001849853stvn:MarkToMarketInterestRateSwapDerivativesMemberifrs-full:InterestRateRiskMember2020-12-310001849853stvn:NotesMemberstvn:DueOn2028Member2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310001849853stvn:OtherFinancialLiabilitiesMember2020-12-310001849853stvn:ResearchAndDevelopmentExpensesMember2021-01-012021-12-310001849853country:MX2019-01-012019-12-310001849853stvn:OtherLiabilityMember2021-12-310001849853stvn:NotesMemberstvn:DueOn2027Member2020-01-012020-12-310001849853stvn:EngineeringSegmentMembersrt:AsiaPacificMember2021-01-012021-12-310001849853stvn:OtherCurrentFinancialAssetsMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMembercurrency:USDstvn:ForwardForeignExchangeContractsMember2020-12-310001849853ifrs-full:MajorPurchasesOfAssetsMemberstvn:NuovaOmpiSRLMember2022-02-232022-02-230001849853ifrs-full:MaterialReconcilingItemsMemberstvn:InterSegmentMember2021-01-012021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberstvn:IndustrialEquipmentMember2020-12-310001849853stvn:MedirioSAMemberstvn:PurchaseOfResidualSharesMember2020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IndustrialEquipmentMember2019-12-310001849853stvn:DepreciationAndAmortizationMember2021-01-012021-12-310001849853stvn:DueOn2021Memberstvn:OverDraftsMember2020-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2021-01-012021-12-310001849853country:DK2021-12-310001849853stvn:PlantAndMachineryMemberstvn:DepreciationAndImpairmentMember2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:IntangibleFixedAssetsInProcessAndAdvancesMember2020-01-012020-12-310001849853stvn:EmployeesMember2020-01-012020-12-310001849853stvn:ResearchAndDevelopmentExpensesMember2019-01-012019-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:BuildingsMember2019-12-310001849853stvn:OtherCurrentFinancialAssetsMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:USD2020-01-012020-12-310001849853ifrs-full:GrossCarryingAmountMember2020-12-310001849853ifrs-full:GoodsOrServicesTransferredOverTimeMember2019-01-012019-12-310001849853stvn:OtherCurrentFinancialAssetsMemberstvn:LaterThanNineMonthsAndNotLaterThanOneYearMemberifrs-full:CurrencyRiskMembercurrency:USDstvn:ForwardForeignExchangeContractsMember2021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OperatingSegmentsMember2020-12-310001849853ifrs-full:EquityAttributableToOwnersOfParentMember2021-12-310001849853stvn:PutAndCallRelatedToFinancialLiabilitiesMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:IndirectControlMemberstvn:OmpiOfAmericaIncMember2021-01-012021-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberifrs-full:GrossCarryingAmountMember2019-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberifrs-full:GrossCarryingAmountMember2021-12-310001849853stvn:CurrentFinancialLiabilitiesMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2021-12-310001849853stvn:FondazioneStevanatoMember2020-01-012020-12-310001849853stvn:MedirioSAMember2019-01-012019-12-310001849853stvn:ExpectedCreditLossesMember2019-01-012019-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2020-12-310001849853stvn:SFEMItaliaSRLMember2019-01-012019-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2019-01-012019-12-310001849853ifrs-full:LegalProceedingsProvisionMember2020-01-012020-12-310001849853ifrs-full:ReportableSegmentsMember2021-01-012021-12-310001849853stvn:PiovesanBarbaraMember2020-01-012020-12-310001849853stvn:InterestRateSwapInCashFlowHedgesMember2021-12-310001849853ifrs-full:UnallocatedAmountsMember2021-12-310001849853stvn:CustomerMemberifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2020-01-012020-12-310001849853ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMember2021-01-012021-12-310001849853ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2021-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BuildingsMember2019-12-310001849853stvn:EngineeringSegmentMemberifrs-full:TopOfRangeMemberifrs-full:MachineryMember2021-01-012021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:BuildingsMember2021-01-012021-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsAndEngineeringSegmentMember2019-01-012019-12-310001849853stvn:CurrentFinancialLiabilitiesMembercurrency:DKKifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMember2020-12-310001849853stvn:EFKHEjendommeApSMember2019-01-012019-12-310001849853stvn:IndustrialAndCommercialEquipmentMember2021-12-310001849853stvn:OtherKeyManagementMember2019-01-012019-12-310001849853stvn:OtherFinancialLiabilitiesMember2021-12-310001849853stvn:PutAndCallRelatedToFinancialLiabilitiesMemberifrs-full:Level3OfFairValueHierarchyMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:StevanatoGroupInternationalSMemberstvn:DirectControlMember2020-01-012020-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMemberstvn:EmployeeBenefitsMember2021-12-310001849853stvn:SocietaAgricolaStellaSRLMember2021-01-012021-12-310001849853ifrs-full:OtherIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMember2021-01-012021-12-3100018498532019-01-012019-12-310001849853stvn:SocietaAgricolaStellaSRLMember2021-11-132021-11-130001849853stvn:NuovaOmpiSRLMemberstvn:DirectControlMember2020-01-012020-12-310001849853ifrs-full:FloatingInterestRateMemberstvn:BankLoansMemberifrs-full:InterestRateRiskMember2021-12-310001849853ifrs-full:NotLaterThanOneYearMemberstvn:OtherLiabilityMember2020-12-310001849853ifrs-full:AccumulatedDepreciationAndAmortisationMemberstvn:IndustrialEquipmentMember2020-01-012020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:SwissfillonAGMember2019-01-012019-12-310001849853ifrs-full:NotLaterThanOneYearMember2020-12-310001849853srt:NorthAmericaMember2021-12-310001849853ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-01-012021-12-310001849853ifrs-full:InterestRateRiskMemberifrs-full:FixedInterestRateMemberstvn:FinancialLiabilitiesDueToOtherLendersMember2021-12-310001849853stvn:HighValueSolutionsMember2019-01-012019-12-310001849853stvn:IndustrialAndCommercialEquipmentMemberifrs-full:GrossCarryingAmountMember2019-12-310001849853ifrs-full:OperatingSegmentsMemberstvn:BiopharmaceuticalAndDiagnosticSolutionsMemberstvn:InterSegmentMember2019-01-012019-12-310001849853stvn:DividendsMember2021-12-310001849853stvn:OverdueBetween90And180DaysMember2021-12-3100018498532018-12-310001849853ifrs-full:FloatingInterestRateMemberifrs-full:InterestRateRiskMemberstvn:FinancialPayablesForShareAcquisitionMember2020-12-310001849853stvn:ManagersMember2021-01-012021-12-310001849853stvn:SwissfillonAGMember2019-12-310001849853stvn:CashSettledAwardsMember2021-01-012021-12-310001849853srt:AsiaPacificMember2021-01-012021-12-310001849853ifrs-full:LaterThanFiveYearsMemberstvn:BorrowingsFromBanksMember2021-12-310001849853stvn:EngineeringSegmentMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2019-01-012019-12-310001849853stvn:OtherCurrentFinancialAssetsMemberifrs-full:CurrencyRiskMemberstvn:ForwardForeignExchangeContractsMembercurrency:USD2021-12-310001849853ifrs-full:WarrantyProvisionMember2021-01-012021-12-310001849853ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-01-012019-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:FinancialCurrentAssetsMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:AssetsUnderConstructionAndAdvancesMember2020-12-310001849853stvn:OtherTangibleAssetsMemberstvn:DepreciationAndImpairmentMember2021-12-310001849853ifrs-full:TopOfRangeMemberstvn:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberstvn:FirstPartnershipAgreementMember2022-02-250001849853stvn:LongTermIncentivePlanPeriodTwoMemberstvn:LongTermIncentivePlanMember2021-12-310001849853ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-12-310001849853stvn:ProvisionForAgentsAndDirectorsSeveranceIndemnityMember2020-12-310001849853stvn:DerivativesFinancialLiabilitiesMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853ifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310001849853stvn:SocietaAgricolaStellaSRLMember2020-12-310001849853ifrs-full:MaterialReconcilingItemsMember2020-01-012020-12-310001849853ifrs-full:ReserveOfCashFlowHedgesMember2019-01-012019-12-310001849853ifrs-full:OtherIntangibleAssetsMemberstvn:AmortizationMember2020-01-012020-12-310001849853stvn:DueOn2024Memberstvn:BankLoansMember2020-12-310001849853stvn:EngineeringSegmentMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2020-01-012020-12-310001849853ifrs-full:Level2OfFairValueHierarchyMemberstvn:OtherNonCurrentFinancialAssetsMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853ifrs-full:RetainedEarningsMember2021-12-310001849853ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001849853stvn:DrugContainmentSystemsMember2020-12-310001849853stvn:PiovesanBarbaraMember2019-01-012019-12-310001849853stvn:AccrualsAndOtherProvisionsMember2020-12-310001849853stvn:BankOverdraftMemberifrs-full:InterestRateRiskMember2021-12-310001849853stvn:EquityInvestmentsOthersMemberifrs-full:RecurringFairValueMeasurementMember2021-12-310001849853stvn:SwissfillonAGMember2021-01-012021-12-310001849853stvn:BankLoansMemberifrs-full:InterestRateRiskMemberifrs-full:FixedInterestRateMember2021-12-310001849853stvn:LaterThanSixYearsMember2021-01-012021-12-310001849853ifrs-full:GrossCarryingAmountMemberstvn:OtherTangibleAssetsMember2020-01-012020-12-310001849853ifrs-full:LaterThanFiveYearsMemberstvn:BorrowingsFromBanksMember2020-12-310001849853stvn:WincklerCoLtdMember2021-01-012021-12-310001849853stvn:ConcessionsLicensesTrademarksAndSimilarRightsMember2020-12-310001849853stvn:SFEMItaliaSRLMember2020-12-310001849853stvn:EuropeMiddleEastAndAfricaMember2019-01-012019-12-310001849853stvn:EngineeringSegmentMemberstvn:RevenuesFromEngineeringMember2021-01-012021-12-310001849853ifrs-full:ForwardContractMember2021-12-310001849853stvn:EFKHEjendommeApSMember2020-01-012020-12-310001849853stvn:CashAndCashEquivalentMemberifrs-full:RecurringFairValueMeasurementMember2020-12-310001849853stvn:BiopharmaceuticalAndDiagnosticSolutionsMemberifrs-full:TopOfRangeMemberifrs-full:MachineryMember2021-01-012021-12-310001849853ifrs-full:IntangibleAssetsUnderDevelopmentMemberstvn:AmortizationMember2021-01-012021-12-310001849853stvn:EuropeMiddleEastAndAfricaMember2021-12-31stvn:Plantstvn:Customeriso4217:EURstvn:Unitiso4217:JPYxbrli:pureutr:sqftiso4217:EURiso4217:DKKiso4217:EURiso4217:JPYiso4217:EURiso4217:USDstvn:Segmentiso4217:EURxbrli:sharesxbrli:sharesstvn:Employediso4217:CHFstvn:Countryiso4217:DKKiso4217:USDiso4217:EURiso4217:CHF

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 20-F/A

Amendment No. 1

 

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

 

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of event requiring this shell company report

 

Commission File Number: 001-40618

 

Stevanato Group S.p.A.

(Exact name of registrant as specified in its charter)

 

Republic of Italy

(State or other jurisdiction of incorporation or organization)

Via Molinella 17

35017 Piombino Dese – Padua

Italy

Telephone: +39 049 931811

(Address, including zip code, and telephone number, including area code, of principal executive offices)

 

Franco Moro

Via Molinella 17

35017 Piombino Dese - Padua

Italy

Telephone: +39 049 931811

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Ordinary shares without par value

STVN

The New York Stock Exchange

 

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:

As of the date of this annual report on Form 20-F/A, there were 295,540,036 of the Registrant’s shares outstanding.

 


 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes ☐ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such a shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).

Yes No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  ☐

Accelerated filer  ☐

Non-accelerated filer  ☒

Emerging growth company  ☒

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant to Section 13(a) of the Exchange Act.

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

U.S.GAAP  ☐

International Financial Reporting Standards as issued by the International Accounting Standards Board  ☒

Other  ☐

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the Registrant has elected to follow:

Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes ☐ No ☐

 

 

 


 

20-F/A EXPLANATORY NOTE

 

Stevanato Group S.p.A. is filing this Amendment No. 1 (the “Form 20-F/A”) to its Annual Report on Form 20-F for the period ended December 31, 2021 (the “Form 20-F”), which was filed with the Securities and Exchange Commission on March 8, 2022, to (i) submit the Interactive Data File (as defined in Rule 11 of Regulation S-T) as Exhibit 101 to the Form 20-F/A in accordance with Rule 405 of Regulation S-T (Exhibit 101 was omitted from the Form 20-F in accordance with the 30-day grace period provided under Rule 405 of Regulation S-T), (ii) provide audited financial statements for the fiscal year ended December 31, 2019, including the report of the independent registered public accounting firm thereto, (iii) include certain additional information to the cover page, Item 4.B Item 5, Item 7.B, Item 14, Item 15, Item 16.C and Item 19 of the Form 20-F, and (iv) correct certain clerical and typographical errors.

 

Except as set forth above, this Form 20-F/A does not modify or update any of the disclosures in the Form 20-F. This Form 20-F/A speaks as of the time of filing of the Form 20-F, does not reflect events that may have occurred subsequent to such filing, and does not modify or update in any way disclosures made in the Form 20-F.

 

i


 

TABLE OF CONTENTS

 

PART I

 

ITEM 1.

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

1

A.

DIRECTORS AND SENIOR MANAGEMENT

1

B.

ADVISERS

1

C.

AUDITORS

1

ITEM 2.

OFFER STATISTICS AND EXPECTED TIMETABLE

1

A.

OFFER STATISTICS

1

B.

METHOD AND EXPECTED TIMETABLE

1

ITEM 3.

KEY INFORMATION

1

A.

RESERVED

1

B.

CAPITALIZATION AND INDEBTEDNESS CAPITALIZATION AND INDEBTEDNESS

1

C.

REASONS FOR THE OFFER AND USE OF PROCEEDS

1

D.

RISK FACTORS

1

ITEM 4.

INFORMATION ON THE COMPANY

33

A.

HISTORY AND DEVELOPMENT OF THE COMPANY

33

B.

BUSINESS OVERVIEW

34

C.

ORGANIZATIONAL STRUCTURE

63

D.

PROPERTY, PLANTS AND EQUIPMENT

63

ITEM 4A.

UNRESOLVED STAFF COMMENTS

64

ITEM 5.

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

64

ITEM 6.

DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

87

A.

DIRECTORS AND SENIOR MANAGEMENT

87

B.

COMPENSATION

90

C.

BOARD PRACTICES

92

D.

EMPLOYEES

97

E.

SHARE OWNERSHIP

97

ITEM 7.

MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

97

A.

MAJOR SHAREHOLDERS

97

B.

RELATED PARTY TRANSACTIONS

98

C.

INTERESTS OF EXPERTS AND COUNSEL

101

ITEM 8.

FINANCIAL INFORMATION

102

A.

CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION

102

B.

SIGNIFICANT CHANGES

102

ITEM 9.

THE OFFER AND LISTING

102

A.

OFFER AND LISTING DETAILS.

102

B.

PLAN OF DISTRIBUTION

102

C.

MARKETS

102

D.

SELLING SHAREHOLDERS

102

E.

DILUTION

102

F.

EXPENSES OF THE ISSUE

102

ITEM 10.

ADDITIONAL INFORMATION

102

A.

SHARE CAPITAL

102

B.

MEMORANDUM OF ASSOCIATION AND BY-LAWS

103

C.

MATERIAL CONTRACTS

127

D.

EXCHANGE CONTROLS

127

E.

TAXATION

127

F.

DIVIDENDS AND PAYING AGENTS

139

G.

STATEMENT BY EXPERTS

139

H.

DOCUMENTS ON DISPLAY

139

I.

SUBSIDIARY INFORMATION

140

ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

140

ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

140

A.

DEBT SECURITIES

140

 

ii


 

B.

WARRANTS AND RIGHTS

140

C.

OTHER SECURITIES

140

D.

AMERICAN DEPOSITARY SHARES

140

PART II

141

ITEM 13.

DEFAULTS, DIVIDEND ARREARAGES and DELINQUENCIES

141

ITEM 14.

MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

141

ITEM 15.

CONTROLS AND PROCEDURES

141

ITEM 16.

RESERVED

141

ITEM 16A.

AUDIT COMMITTEE FINANCIAL EXPERT

141

ITEM 16B.

CODE OF ETHICS

141

ITEM 16C.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

142

ITEM 16D.

EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

142

ITEM 16E.

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

142

ITEM 16F.

CHANGE IN REGISTRANTS CERTIFYING ACCOUNTANT

142

ITEM 16G.

CORPORATE GOVERNANCE

142

ITEM 16H.

MINE SAFETY DISCLOSURE

143

ITEM 16I.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

143

PART III

144

ITEM 17.

FINANCIAL STATEMENTS

144

ITEM 18.

FINANCIAL STATEMENTS

144

ITEM 19.

EXHIBITS

145

 

iii


 

Explanatory Note

Throughout this annual report, unless the context otherwise requires, references to “Stevanato Group S.p.A.”, “Stevanato”, the “Company”, “we”, “us”, “Group”, “our” and words of similar import refer to Stevanato Group S.p.A. and its consolidated subsidiaries.

Unless otherwise indicated, all references to “€”, “EUR” and “Euro” in this annual report are to, and amounts are presented in, euros. All references to “US$” and “$” are to U.S. Dollars.

Financial Statements

We present in this annual report the audited consolidated financial statements as of and for the year ended December 31, 2021, 2020 and 2019. These financial statements were prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).

All references herein to “our financial statements”, “our audited consolidated financial information”, or “our audited consolidated financial statements”, are to Stevanato Group’s consolidated financial statements included elsewhere in this annual report.

This financial information should be read in conjunction with “Operating and Financial Review and Prospects”, and “our audited consolidated financial statements”, including the notes thereto, included elsewhere in this annual report.

Our fiscal year ends on December 31. References in this annual report to a fiscal year, such as “fiscal year 2021,” relate to our fiscal year ended on December 31 of that calendar year.

As of the date of this annual report, our authorized share capital is €21,698,480.00 divided into 295,540,036 shares without par value, including 34,103,005 ordinary shares and 261,437,031 Class A shares. On March 4, 2021, the shareholders’ meeting approved a share split following which the then existing 20,002 shares have been split into a total of 100,010,000 ordinary shares with no par value, without changing the amount of the share capital. On July 1, 2021 the shareholders’ meeting approved a further share split following which all the existing 100,010,000 shares have been split into a total of 272,427,240 shares in the ratio of 2,724 new shares post-split for each share outstanding prior to the share split. In connection with the split that occurred on July 1, 2021, all of the ordinary shares held by Stevanato Holding S.r.l. and the ordinary shares held in treasury were converted into Class A shares.

On July 20, 2021 we completed our initial public offering, at completion of which 22,400,000 ordinary shares were offered by us and 9,600,000 ordinary shares were offered by Stevanato Holding S.r.l.. On August 18, 2021 the underwriters further purchased 712,796 newly issued ordinary shares from us and 305,484 ordinary shares from Stevanato Holding S.r.l..

Special Note Regarding Non-GAAP Financial Measures

This annual report presents our EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, CAPEX and Free Cash Flow, which are non-GAAP financial measures, and their reconciliations to the nearest measure as defined by IFRS, for the convenience of investors.

EBITDA is defined as net profit before income tax expenses, net financial expenses, including share of profit of associates, amortization and depreciation. Adjusted EBITDA is defined as EBITDA as adjusted for certain income and costs expected to occur infrequently, and that management considers not reflective of ongoing operational activities of the company. EBITDA is presented to aid management in their analysis of the performance of the Group and to assist in the comparison of our performance with that of our competitors. Adjusted EBITDA is provided in order to present how the underlying business has performed excluding the impact of certain non-recurring items, which may alter the underlying performance and impair comparability of results between periods. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA for a period by total revenue for the same period.

Adjusted Operating Profit represents Operating Profit as adjusted for certain income and costs expected to occur infrequently, and that management considers not reflective of ongoing operational activities. Adjusted Operating Profit is provided in order to present how the underlying business has performed excluding the impact of the adjusting items, which may alter the underlying performance and impair comparability of results between the periods. Adjusted Operating Profit Margin is calculated by dividing Adjusted Operating Profit for a period by total revenue for the same period.

iv


 

Capital expenditure, or CAPEX, is the sum of investment amounts on tangible fixed assets and intangible assets during the period (excluding right-of-use assets recognized during the period in accordance with IFRS 16—Leases). These investment activities consist of acquisitions of property and equipment and intangible assets.

Free Cash Flow is defined as cash flows from operating activities excluding interests paid and received, less investments in property, plant and equipment and intangible assets on a paid-out cash basis.

Management uses EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, CAPEX and Free Cash Flow to monitor the underlying performance of the business and its operations. These measures are used by different companies for differing purposes and are often calculated in ways that reflect the circumstances of those companies. You should exercise caution in comparing these measures as reported by us to the same or similar measures as reported by other companies. These non-GAAP financial measures may not be comparable to similarly titled metrics of other companies.

EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, CAPEX and Free Cash Flow are not measurements of performance under IFRS or any other generally accepted accounting principles, and you should not consider them as an alternative to loss for the period, operating loss or other financial measures determined in accordance with IFRS. These measures have limitations as analytical tools, and you should not consider them in isolation. See “Summary Consolidated Financial Data—Non-GAAP Financial Measures” for more detail on these limitations of EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, CAPEX and Free Cash Flow. Accordingly, prospective investors should not place undue reliance on these non-GAAP financial measures contained in this annual report.

Market Share and Other Information

This annual report contains data related to economic conditions in the market in which we operate. The information contained in this annual report concerning economic conditions is based on publicly available information from third-party sources that we believe to be reasonable. Market data and certain industry forecast data used in this annual report were obtained from internal reports and studies, where appropriate, as well as estimates, market research, publicly available information and industry publications. We obtained the information included in this annual report relating to the industry in which we operate, as well as the estimates concerning market shares, through internal research, public information and publications on the industry prepared by official public sources.

There are a number of studies that address either specific market segments, or regional markets, within our industry. We have reviewed and analyzed data collected by, among others, IQVIA, Alira Health, Roots Analysis, Markets and Markets Research Pvt Ltd., Grand View Research and Evaluate MedTech and Global Data UK Ltd (“Global Data”). However, given the rapid changes in our industry and the markets in which we operate, no industry research that is generally available covers all of the trends we view as key to understanding our industry and our place in it as providers of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries.

Due to the evolving nature of our industry and competitors, we believe that it is difficult for any market participant, including us, to provide precise data on the market or our industry. However, we believe that the market and industry data we present in this annual report provide accurate estimates of the market and our place in it. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as other forward-looking statements in this annual report. We have no reason to believe any of this information or these reports are inaccurate in any material respect and believe and act as if they are reliable. In addition, the data that we compile internally and our estimates have not been verified by an independent source. None of the publications, reports or other published industry sources referred to in this annual report were commissioned by us or prepared at our request. Except as disclosed in this annual report, we have not sought or obtained the consent of any of these sources to include such market data in this annual report.

Rounding

We have made rounding adjustments to some of the figures included in this annual report. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

v


 

Trademarks, Service Marks and Trade Names

We have proprietary rights to trademarks used in this annual report that are important to our business, many of which are registered under applicable intellectual property laws. Solely for convenience, the trademarks, service marks, logos and trade names referred to in this annual report are without the ® and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This annual report contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this annual report are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies’ trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

vi


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical or present facts or conditions. These forward-looking statements are contained principally in the sections entitled “Risk Factors,” “Use of Proceeds,” “Operating and Financial Review and Prospects” and “Business.” These statements relate to events that involve known and unknown risks, uncertainties and other factors, including those listed under “Risk Factors,” which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, these forward-looking statements which reflect our current views with respect to future events and financial performance. The words “believe,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect” and similar expressions identify forward-looking statements. Forward-looking statements contained in this annual report include, but are not limited to, statements about:

o
our future financial performance, including our revenue, operating expenses and our ability to maintain profitability;
o
our expectations regarding the development of our industry and the competitive environment in which we operate; and
o
our goals and strategies; and our proposed use of proceeds.

The forward-looking statements in this document are based upon various assumptions, many of which are based, in turn, upon further assumptions, including, without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions are reasonable, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors and matters discussed elsewhere in this annual report, important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include:

o
our product offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation;
o
we must develop new products and enhance existing products, adapt to significant technological and innovative changes and respond to introductions of new products by competitors to remain competitive;
o
our backlog might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our backlog;
o
if we fail to maintain and enhance our brand and reputation, our business, results of operations and prospects may be materially and adversely affected;
o
we are highly dependent on our management and employees. Competition for our employees is intense, and we may not be able to attract and retain the highly skilled employees that we need to support our business and our intended future growth;
o
our business, financial condition and results of operations depend upon maintaining our relationships with suppliers and service providers;
o
our business, financial condition and results of operations depend upon the availability and price of high-quality materials and energy supply and our ability to contain production costs;
o
significant interruptions in our operations could harm our business, financial condition and results of operations;

vii


 

o
our manufacturing facilities are subject to operating hazards which may lead to production curtailments or shutdowns and have an adverse effect on our business, results of operations, financial condition or cash flows;
o
our business may be harmed if our customers discontinue or spend less on research, development, production or other scientific endeavors;
o
we may face significant competition in implementing our strategies for revenue growth in light of actions taken by our competitors; and
o
any other risk we mention in the section “Risk Factors.”

We caution readers of this annual report not to place undue reliance on these forward-looking statements, which speak only as at their dates. We undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, we cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement.

viii


 

PART I

ITEM 1. Identity of Directors, Senior Management and Advisers

A.
Directors and Senior Management

Not applicable.

B.
Advisers

Not applicable.

C.
Auditors

Not applicable.

ITEM 2. Offer Statistics and Expected Timetable

A.
OFFER STATISTICS

Not applicable.

B.
METHOD AND EXPECTED TIMETABLE

Not applicable.

ITEM 3. Key Information

A.
reserved
B.
Capitalization and INDEBTEDNESS Capitalization and Indebtedness

Not applicable.

C.
Reasons for the Offer and Use of Proceeds

Not applicable.

D.
Risk Factors

Our business, financial condition, results of operations and liquidity can suffer materially as a result of any of the risks described below. While we have described all of the risks we consider material, these risks are not the only ones we face. We are also subject to the same risks that affect many other companies, such as technological obsolescence, labor relations, geopolitical events, climate change and risks related to the conducting of international operations. Additional risks not known to us or that we currently consider immaterial may also adversely impact our businesses. Our businesses routinely encounter and address risks, some of which may cause our future results to be different—sometimes materially different—than we presently anticipate.

 

Summary

 

The following summarizes some, but not all, of the risks provided below. Please carefully consider all of the information discussed in this Item 3.D. “Risk Factors” in this annual report on Form 20-F for a more thorough description of these and other risks.

 

Risks Relating to our Business and Industry

Our product offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation.

1


 

We must develop new products and enhance existing products, adapt to significant technological and innovative changes and respond to introductions of new products by competitors in order to remain competitive.
Our backlog might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our backlog.
If we fail to maintain and enhance our brand and reputation, our business, results of operations and prospects may be materially and adversely affected.
We are highly dependent on our management and employees. Competition for our employees is intense, and we may not be able to attract and retain the highly skilled employees that we need to support our business and our intended future growth.
Our business, financial condition and results of operations depend upon maintaining our relationships with suppliers and service providers.
Our business, financial condition and results of operations depend upon the availability and price of high‑quality materials and energy supply and our ability to contain production costs.
Significant interruptions in our operations could harm our business, financial condition and results of operations.
As a consequence of the COVID-19 pandemic, sales of syringes and vials to and for vaccination programs globally increased resulting in a revenue growth acceleration. The demand for such products may shrink, if the need for COVID-19 related solutions declines.
Our manufacturing facilities are subject to operating hazards which may lead to production curtailments or shutdowns and have an adverse effect on our business, results of operations, financial condition or cash flows.
We may face significant competition in implementing our strategies for revenue growth in light of actions taken by our competitors.
Our global operations are subject to international market risks that may have a material effect on our liquidity, financial condition, results of operations and cash flows.
We are required to comply with a wide variety of laws and regulations and are subject to regulation by various federal, state and foreign agencies.
If relations between China and the United States deteriorate, our business in the United States and China could be materially and adversely affected.
Cyber security risks and the failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions, could result in damage to our reputation, data integrity and/or subject us to costs, fines or lawsuits under data privacy or other laws or contractual requirements.

 

Risks Relating to our Intellectual Property

Our trade secrets may be misappropriated or disclosed, and confidentiality agreements with directors, employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.
If we are unable to obtain and maintain patent protection for our technology, products and potential products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
We depend in part on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our potential products.

2


 

Third parties may assert claims against us alleging infringement, misappropriations or other violations of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of our products and potential products, or prohibit our use of proprietary technology or sale of products.
We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful and have an adverse effect on the success of our business.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

 

Risks Relating to our Shares

The market price of our ordinary shares may fluctuate significantly due to a variety of factors.
The dual class structure of our shares may adversely affect the value and trading market for the ordinary shares.
If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our ordinary shares and our trading volume could decline.
Our voting control is concentrated.
Future sales, or the possibility of future sales, of a substantial number of our shares could adversely affect the price of our ordinary shares.
The obligations associated with being a public company require significant resources and management attention.

 

Risk Factors

Risks Relating to our Business and Industry
Our product offerings are highly complex, and, if our products do not satisfy applicable quality criteria, specifications and performance standards, we could experience lost sales, delayed or reduced market acceptance of our products, increased costs and damage to our reputation.

Most of our products are highly exacting and complex due to their use for containment and injection of biologic drugs and vaccines. Providing high-quality products that deliver specificity, sensitivity and consistency, together with extensive product validation data is a fundamental driver of customer loyalty and our reputation with life sciences researchers. Our operating results depend on our ability to execute and, when necessary, improve our global quality control systems, including our ability to effectively train and maintain our employees with respect to quality control. A failure of our global quality control systems could result in problems with facility operations or preparation or provision of defective or non-compliant products which could ultimately cause harm to the final user. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with critical materials and components, failure by one or more of our suppliers to meet our quality requirements, or environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production altogether. Although we currently hold an insurance policy that covers liabilities for defective products and product recalls in amounts we believe to be adequate for our business, our coverage may not be adequate to insure against all product liability claims that may arise which may be particularly high in case failure of our products to meet the appropriate quality standards cause product recalls or damages to our customers or ultimate users. As a result of this, product defect claims or product recalls may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Our success depends on our customers’ confidence that we can provide reliable, consistently high-quality products, which also requires us to provide validated data to support our customers’ use of our products. We believe that customers in our target markets are likely to be particularly sensitive to our products failing to meet the specifications

3


 

shown on our data sheets. Our reputation and the public perception of our products and technologies may be impaired if our products fail to perform as expected or fail to meet applicable quality criteria, specifications or performance standards. If our products experience, or are perceived to experience, a material defect or error, this could result in loss or delay of sales, damaged reputation, diversion of development resources and increased insurance or warranty costs, any of which could harm our business. These risks are amplified in respect of our new product lines as we implement appropriate quality control criteria. We are reliant to an extent on customer feedback on the quality of our products, and it may take additional time for new products to meet the desired quality standards. Any defects or errors could also result in our inability to timely deliver products to our customers, which could in turn cause disruptions to our customers’ ability to obtain results, narrowing the scope of the use of our products and ultimately hindering our or their success in relevant markets. Even after any underlying concerns or problems are resolved, any lingering concerns in our target markets regarding our technology, product defects or performance standards could continue to result in lost sales, delayed market acceptance and damaged reputation, among other things. If problems in preparation or manufacture of a product, failure to meet required quality standards for that product or other product defects are not discovered before such product is released to our customers, we may be subject to adverse legal or regulatory actions, including halting of manufacturing and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such problems or failures subject us to other litigation claims, including claims from our customers for reimbursement of the cost of lost or damaged materials. Our customers also require specific information regarding our products and their uses, and any inaccuracies in this information could lead to products being sold for the wrong uses and may result in our having to refund or replace the products in question. Any of the above problems may adversely affect our reputation, business, financial condition and results of operations.

We must develop new products and enhance existing products, adapt to significant technological and innovative changes and respond to introductions of new products by competitors in order to remain competitive.

We sell our products in industries that are characterized by significant technological changes, frequent new product and technology introductions and enhancements and evolving regulatory requirements and industry standards. As a result, our customers’ needs continue to evolve and our products may be superseded by new technologies (for instance if certain drugs are no longer administered through injectables) or their demand may decline. For instance, as our sales and profitability are largely dependent on the sale of products delivered by injection, if our customers reconfigure their drug product or develop new drug products requiring less frequent dosing, our sales and profitability may suffer. Likewise, if we do not appropriately innovate and invest in new products and technologies, and be open to broadening the scope of our offering, our product offerings may become less desirable in the markets we serve, and, although changing providers is a lengthy process for our customers, they could move to new technologies offered by our competitors, especially if such competitors are able to react more directly and effectively to a customer’s specific demand. Though we believe customers in our markets display a significant amount of loyalty to a particular product, we also believe that because of the initial time investment required by many of our customers to reach a purchasing decision for a new product, it may be difficult to regain a customer once that customer purchases a product from a competitor.

Moreover, there is a risk that the significant amounts of time and resources (approximately 3.5% of our 2021 revenue) that we invest in research, development and identification of new products would not result in the expected positive results for our business. If we invest our resources into a new product or product enhancement that fails to meet our high-quality standards and market expectations or does not perform in the way it was intended, this could adversely affect our business. Our current customers may decide not to purchase these new products or product enhancements and / or purchase a product from a competitor or cease doing business with us altogether. It can take significant time to identify an unmet customer need and develop a product to meet that need, and to the extent we fail to obtain desired levels of market acceptance, our business, financial condition or results of operations could be adversely affected.

Our estimates of our addressable market include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. Industry publications, research, surveys, studies and forecasts generally state that the information they contain has been obtained from sources believed to be reliable. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for our products may be smaller than we expect, and as a result, our product revenue may be limited and our business, financial condition or results of operations could be adversely affected.

4


 

Our backlog might not accurately predict our future revenue, and we might not realize all or any part of the anticipated revenue reflected in our backlog.

Our backlog represents, as of a point in time, estimated future revenue for work not yet completed under (i) specific purchase orders, with regards to our Biopharmaceutical and Diagnostic Solution segment, and (ii) certain one-off agreements, with regards to our Engineering segment. We recognize direct revenue over the life of the contract based on our performance of services under the contract. Contracts may be terminated or delayed by our customers or regulatory authorities for reasons beyond our control. To the extent projects are delayed, the timing of our revenue could be affected. In the event a customer terminates a contract, we are generally entitled to be paid for services rendered through the termination date and for services provided in winding down the project. However, we are generally not entitled to receive the full amount of direct revenue reflected in our backlog in the event of a contract termination. The duration of the projects in our backlog, and the related revenue recognition, ranges from several months to many years. For orders that are placed inside a contractual firm period, we generally have a contractual right to payment in the event of cancellation. Fluctuations in our reported backlog levels also result from the timing and order pattern of our customers who often seek to manage their level of inventory on hand. Because of customer ordering patterns, our backlog reported for certain periods may fluctuate and may not be indicative of future results. A number of factors may affect backlog and the direct revenue generated from our backlog, including:

the size, complexity and duration of projects; and
the cancellation or delay of projects.

Our backlog at December 31, 2021 was approximately €880.0 million compared to €606.7 million as of December 31, 2020. Although an increase in backlog will generally result in an increase in future direct revenue to be recognized over time (depending on future contract modifications, contract cancellations and other adjustments), an increase in backlog at a particular point in time does not necessarily correspond to an increase in direct revenues during a particular period. The timing and extent to which backlog will result in direct revenue depends on many factors, including the timing of commencement of work, the rate at which we perform services, scope changes, cancellations, delays, receipt of regulatory approvals and the nature, duration, size, complexity and phase of the studies. In addition, delayed projects remain in backlog until they are canceled. As a result of these factors, our backlog is not necessarily a reliable indicator of future direct revenue and we might not realize all or any part of the direct revenue from the authorizations in backlog as of any point in time.

If we fail to maintain and enhance our brand and reputation, our business, results of operations and prospects may be materially and adversely affected.

We believe that maintaining and enhancing our brand and reputation are of significant importance to the success of our business. We work to set a very high standard for the quality of our products and our ethical business practices, and we believe that this has been crucial to our success. We have employed and will continue to employ different types of consumer experience and interaction touchpoints designed to gauge consumer satisfaction with our products, and we also engage in rigorous product validation in order to continue to improve our product quality. We cannot assure you, however, that these activities will be successful or that we will be able to continue to maintain our brand and reputation as we expect. If our brand strength deteriorates, or if our brand is no longer associated with high-quality products, it could lead to fewer publication citations for our products, which could in turn further weaken our brand recognition and reputation. In addition, our competitors may increase the intensity of their consumer interactions or customer feedback processes, which may force us to increase our advertising spend to engage with our customer base and maintain brand and reputational awareness.

In addition, any negative publicity relating to our products or services, regardless of its veracity, could harm our brand and the perception of our brand in the market. With an increasing global focus on ethical business practices and good corporate behavior, and with such issues directly influencing consumer behavior, any failure to achieve or maintain the levels of corporate governance, social and environmental impact and corporate behaviors expected of us, including demonstrating dedication to the benefits of diversity, could negatively impact our brand and reputation. If our brand is harmed, we may not be able to gain new customers or continue to maintain positive relationships with our customers, and our business, prospects, financial condition and results of operations could be materially and adversely affected.

5


 

Part of our growth strategy is to increase direct customer interactions in multiple countries. Failure to anticipate and react to particular geographic requirements and sensitivities may have a negative impact on our brand and reputation, which may result in a decrease in sales or sales growth in such countries, which may adversely affect our business, prospects, financial condition and results of operations.

We are highly dependent on our management and employees. Competition for our employees is intense, and we may not be able to attract and retain the highly skilled employees that we need to support our business and our intended future growth.

Our success largely depends on the skills, experience and continued efforts of our management, including our Executive Chairman, our Chief Executive Officer and our senior leadership, as well as of our research and development and highly skilled employees. The replacement of certain members of our global leadership team would likely involve the expenditure of significant time and financial resources, and the loss of any such individual may significantly delay or prevent the achievement of our business objectives. Likewise, the members of our research and development team and our highly skilled employees, who our customers and competitors often seek to engage, may be difficult to replace in light of their sophisticated skills and experience and a shortage of such employees could disrupt our operations. As we continue to grow, our success also depends on our ability to attract, motivate and retain highly qualified individuals who will also fit within our culture. Competition for senior management and other personnel in our industry is intense, and the pool of suitable candidates is limited. If qualified personnel become scarce or difficult to attract or retain in our industry for compensation-related or other reasons, we could experience higher labor, recruiting or training costs. Further, new hires may require significant training and time before they achieve full productivity and may not become as productive as we expect. The failure to attract, retain and properly motivate members of our senior management team and other employees, to find suitable replacements for them in the event of death, illness or their desire to pursue other professional opportunities, or to maintain our corporate culture as we continue to grow, could have a negative effect on our operating results.

Our business, financial condition and results of operations depend upon maintaining our relationships with suppliers and service providers.

Our ability to sustain our income has been, and will continue to be, dependent in part on our ability to obtain favorable terms from our suppliers and services providers, including logistics services providers. These terms may change from time to time, and such changes could adversely affect our gross margins over time. In addition, our results of operations and cash flows could be adversely impacted by the acceleration of payment terms to our suppliers and/or the imposition of more restrictive credit terms and other contractual requirements. Further, if for any reason we enter into a contract with a supplier on unfavorable terms, it may harm our ability to negotiate our future contracts with that supplier or with other suppliers.

The loss of one or more of our large suppliers including as a result of consolidation, a material reduction in their supply of products or provision of services to us, extended disruptions or interruptions in their operations or material changes in the terms we obtain from them, could have a material adverse effect on our business, financial condition and results of operations.

Our business, financial condition and results of operations depend upon the availability and price of high-quality materials and energy supply and our ability to contain production costs.

Our operations depend upon our ability to obtain high-quality materials and energy supply at reasonable prices, therefore maintaining low production costs. Our ability to maintain an adequate supply of such materials and energy could be impacted by the availability and price of those materials and energy, the failure to maintain relationships with suppliers and any of such materials being proven to be toxic or otherwise inadequate to be used for the intended purpose. While we may seek to minimize the impact of price increases and potential shortages by, among other things, entering into long-term supply agreements, increasing our own prices and implementing cost-saving measures, our earnings and cash flows could be adversely affected in the event these measures are insufficient to cover our costs. With respect to energy supply, the current conflict between Russia and Ukraine and the financial and economic sanctions imposed by the European Union, the U.S., the United Kingdom and other countries and organizations against officials, individuals, regions, and industries in Russia, Ukraine and Belarus may negatively impact our ability source gas at commercially reasonable terms, or at all. Moreover, while we aim to maintain a large network of product suppliers, we are unable to predict any interruption or disruption in service from our key suppliers, particularly in light

6


 

of the COVID-19 pandemic. In particular, for some of the materials we use in our production cycles, including glass tubes and DuPont synthetic fiber Tyvek®, we have a limited number of (or a single-source) suppliers worldwide, and selecting new suppliers would be a lengthy and time consuming process. Any interruption or disruption in service from particular suppliers of materials means that interruptions or stoppages in such deliveries could adversely affect our operations until arrangements with alternative suppliers. If this occurs, we could expend substantial resources and time in re-establishing relationships with third-party suppliers that meet the appropriate quality, cost and regulatory requirements needed for commercially viable manufacture of our products. If we are unable to obtain the materials we need at reasonable prices or at all, we may not be able to produce certain of our products at a marketable price or at all. If our supply of materials and components is adversely affected, including as a result of the COVID-19 pandemic, we could damage our relationship with current and prospective customers and our operating results and financial condition could be adversely affected.

Moreover, we are dependent upon the ability of our suppliers to provide materials that meet our quality standards, as well as delivery schedules. Our suppliers’ failure to provide expected materials that meet such criteria could adversely affect production schedules and contract profitability.

The continued supply of high-quality third-party materials and energy from our suppliers is subject to a number of risks, including:

the destruction of or damage to our suppliers’ facilities or their distribution infrastructure;
work stoppages or strikes by our suppliers’ employees;
the failure of our suppliers to provide materials of the requisite quality or in compliance with strict specifications;
the failure of essential equipment at our suppliers’ plants;
the failure of our suppliers to satisfy import and export control laws for goods that we purchase from them;
the failure of our suppliers to meet regulatory standards where applicable;
the failure, shortage or delay in the delivery of materials to our suppliers;
contractual amendments and disputes with our suppliers; and
inability of our suppliers to perform as a result of the weakened global economy, terrorism, war and other armed hostilities (such as Russia's invasion of Ukraine and financial and economic sanctions imposed in response thereto), the COVID-19 pandemic or otherwise.

 

Moreover, the recent global economic cost inflation trends could unfavorably impact pricing from our suppliers, which in turn could impact our gross margins to the extent we are unable to pass along price differences to our customers.

If we experience problems with suppliers, we may not be able to find acceptable alternatives, and any such alternatives could result in increased costs for us and possible forward losses on certain contracts. Even if acceptable alternatives are found, the process of locating and securing such alternatives might be disruptive to our business, might lead to termination of our supply agreements with our customers and might disrupt the operations of our customers leading to potential claims, any of which could adversely affect our business, financial condition and results of operations.

Significant interruptions in our operations could harm our business, financial condition and results of operations.

Manufacturing, distribution, service and logistics problems can and do arise, particularly in light of the COVID-19 pandemic (including the spread of variants and mutant strains, such as the omicron variant which caused higher rates of absenteeism in some of our European factories in January 2022), and any such problems could have a significant impact on our business, financial condition and results of operations. Accordingly, any significant disruptions to the operations of our manufacturing or distribution centers or logistics providers for any reason, including labor relations issues, power interruptions, severe weather, fire or other circumstances beyond our control could cause our operating

7


 

expenses to increase without coverage or compensation or seriously harm our ability to fulfill our customers’ orders or deliver products on a timely basis, or both. Likewise, our ability to meet our customers’ needs and expectations may be frustrated by delays, issues or interruptions in ramping up new production lines or plants. We must also maintain sufficient production capacity in order to meet anticipated customer demand, which carries fixed costs that we may not be able to offset if orders slow, which would adversely affect our operating margins. If we are unable to manufacture our products consistently, in sufficient quantities and on a timely basis, our sales, gross margins and our other operating results will be materially and adversely affected. Prompt shipment of our products is also very important to our business. If we experience significant delays in our manufacturing, shipping or logistics processes, this could cause disruption to our customers and damage our current and future customer relationships and may adversely affect our business. Such delays may also adversely impact our new product development. For example, if we were to lose one of our sites where new product development is undertaken, we may not be able to transfer or replicate that product development at another site, with the result of lost time and financial costs of developing the new product. We may also use high-risk chemicals in the manufacture of certain of our products, which are subject to handling risks, and any disruption in our ability to source or appropriately store these chemicals could adversely affect our manufacturing operations.

As a consequence of the COVID-19 pandemic, sales of syringes and vials to and for vaccination programs globally increased resulting in a revenue growth acceleration. The demand for such products may shrink, if the need for COVID-19 related solutions declines.

Since the outbreak of COVID-19, we have increased production capacity to support our customers’ efforts to provide a rapid response to COVID-19. In this context we have been providing: (i) glass vials and syringes to approximately 90% of currently marketed vaccine programs, according to our estimates based on public information (WHO, EMA, FDA); and (ii) plastic diagnostic consumables for the detection and diagnosis of COVID-19. COVID-19 has generated increased demand for our products and services, further enabling us to accelerate our growth strategy. Going forward, we expect demand for syringes, vials and related products and services to remain elevated as the COVID‑19 vaccine and treatment programs continues to roll-out globally and as our customers contemplate the transition from multi-dose formats to single-dose formats. In addition, we expect continued tailwinds as epidemic preparedness, including the ongoing global COVID-19 vaccine rollout, booster shot distribution, and new vaccination programs, remains a priority for governments.

There remains uncertainty around the magnitude of the long-term impact of COVID-19 on demand for our syringes, vials, plastic diagnostic consumables, and related products and services, which may shrink rapidly in the future, for instance:

as the pandemic abates or infection rates decline;
as governmental and health authorities relax rules on mandatory COVID-19 testing;
as vaccination programs are completed or re-vaccination / booster are not required; or
where injectable vaccines are replaced with other vaccines not requiring our products and services.

A lower rate of increase or a decline in sales of syringes and vials to and for vaccination programs, plastic diagnostic consumables for COVID-19 testing, and related products and services could adversely affect our business, financial condition and results of operations.

Our manufacturing facilities are subject to operating hazards which may lead to production curtailments or shutdowns and have an adverse effect on our business, results of operations, financial condition or cash flows.

Certain of our manufacturing processes involve heating glass to extremely high temperatures, forming plastic and operating heavy machinery and equipment, which entail a number of risks and hazards, including industrial accidents, leaks and ruptures, explosions, fires, mechanical failures and environmental hazards, such as spills, storage tank leaks, discharges or releases of toxic or hazardous substances and gases, including into the environment. Any of these events, which are generally more likely to occur as our machines approach time for refurbishment, could lead to requirements for environmental remediation and civil, criminal and administrative sanctions and liabilities. These hazards may cause unplanned business interruptions (also as a consequence of remediation actions), unscheduled downtime, transportation interruptions, personal injury and loss of life, severe damage to or the destruction of property and

8


 

equipment, environmental contamination and other environmental damage, civil, criminal and administrative sanctions and liabilities and third-party claims, any of which may have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, under applicable local laws, including Italian law, our directors and officers may be subject to criminal liability, in connection with injuries occurred to our employees, as a result of workplace health and safety violations by reason of their position as employers (posizione di garanzia). Convictions of our directors and officers could negatively impact our reputation. Moreover, due to the long industrial history of our manufacturing facilities and the subsequent lack of detailed information regarding historical waste and chemical storage and disposal, the risk of soil, water or groundwater contamination and related civil, administrative and criminal liabilities cannot be eliminated.

We may face significant competition in implementing our strategies for revenue growth in light of actions taken by our competitors.

In each business segment in which we operate, we face significant competition, with many competitors focusing on specific regions, customers and/or specific product segments. Competitors range from smaller, specialized companies, which may be able to more quickly respond to customers’ specific needs, to large multinational companies who provide a full suite of products, which may have greater financial, marketing, operational and research and development resources than we do. Such greater resources may allow our competitors to respond more effectively with new, alternative or emerging technologies. Failure to anticipate and respond to our competitors’ actions may impact our future sales and earnings, in particular failure to react to competitors strengthening their brand, marketing or customer experience may negatively impact our ability to attract and retain customers.

We are pursuing a number of strategies to maintain and improve our revenue growth, including:

expand our global market position in primary containment systems;
leverage leadership in primary containment to build market position in drug delivery systems;
accelerate market penetration in life sciences systems;
increase our investments in R&D to address unmet market needs;
build on our expertise in manufacturing, assembly and inspection systems for primary containers and complex, multi-component systems;
leverage our scientific and engineering capabilities across the drug development timeline;
leverage our global geographical presence as a platform to increase our penetration in the North American and APAC regions; and
selectively pursue acquisitions and technology partnerships to augment and expand our product and service portfolio.

We may not be able to successfully implement these strategies, and these strategies may not result in the desired growth of our business. Failure to anticipate and respond to our competitors’ actions may adversely affect our business, financial condition and results of operations.

Our business may be harmed if our customers discontinue or spend less on research, development, production or other scientific endeavors.

Our customer base includes leading pharmaceutical, biologic, diagnostic and medical device companies worldwide. Many factors, including public policy spending priorities, available resources and product and economic cycles, have a significant effect on the capital spending policies of these entities. For instance, any change in the international healthcare systems, including the Patient Protection and Affordable Care Act (the “PPACA”) in the U.S., resulting in a reduced ability of pharmaceutical companies and healthcare providers to receive reimbursements by government authorities, private insurers and other third-party payers for the costs of our products, could result in reduced demand for our products.

9


 

Fluctuations in the research and development budgets of our customers could have a significant effect on the demand for our products. Our customers determine their research and development budgets based on several factors, including the need to develop new products, continued availability of governmental and other incentives and funding, competition and the general availability of resources. Any reduction in research and development budgets or a shift of any funding source currently allocated to our business sector to different areas of research, could adversely affect our business, financial condition and results of operations.

The loss of a significant number of customers or a reduction in orders from a significant number of customers could reduce our sales and harm our operating results.

Our operating results could be negatively affected by the loss of revenue from a significant number of our customers. Our sales are fairly well distributed, with 41.7% of our revenues deriving from our top ten customers and no individual customer representing more than 10.0% of revenues in 2021. However, consolidation within our customer base, including, in particular, among pharmaceutical companies, may give larger customers greater bargaining and buying power and operational sophistication, which can enable them to operate with reduced inventories. In addition, consolidation among our customers may lead them to rely on a reduced number of suppliers, with no assurance that they will continue using our products.

We maintain close business relationships with certain customers, working closely to build the specific custom tools they need, which will then become part of our product portfolio. Our operating results could be adversely affected by the loss of a significant number of these customers, particularly during the product development phase.

Our contracts generally do not contain minimum purchase requirements, and a significant portion of our sales are on a purchase order basis. Therefore, our customers are generally not obligated to purchase any fixed quantities of products, and they may stop placing orders with us at any time. If a significant number of customers purchase fewer of our products, defer orders or fail to place additional orders with us for any reason, our sales could decline, and our operating results may not meet our expectations. In addition, if those customers order our products, but fail to pay on time or at all, our liquidity and operating results could be adversely affected.

The level and timing of orders placed by our customers vary for different reasons, including individual customer strategies, the introduction of new technologies, the desire of our customers to reduce their exposure to any single supplier and general economic conditions. If we are unable to anticipate and respond to the demands of our customers, if we have an inadequate supply of products, insufficient capacity in our sites or if we experience any disruptions to our supply chain or distribution network, we may lose customers. Alternatively, we may have excess inventory or excess capacity, and either of these factors may have a material adverse effect on our business, financial condition and results of operations.

Our business may suffer if we do not successfully manage our current and potential future growth.

Over the last 70 years we have consistently expanded our operations and anticipate expanding further as we pursue our long-term growth strategy. The key elements of our growth strategy include, among other things, the expansion of our global market position in primary containment and drug delivery systems, accelerating penetration in life sciences systems, increasing our investments in research and development, building on our expertise in manufacturing, assembly and inspection systems for primary containers and complex, multi-component systems, leveraging our scientific and engineering capabilities, increasing our penetration in the North American and APAC regions and selectively pursuing acquisitions and technology partnerships to augment and expand our product and service portfolio. In particular, we are using part of the proceeds of the Offering to further expand our manufacturing facilities in Piombino Dese (Italy) and to establish new plants for EZ-Fill® products, with strong focus on biologics and vaccines, in Indiana (U.S.) and Zhangjiagang (China) (focusing also on engineering) and pursue strategic acquisitions to broaden our offering, our technical know-how and our international footprint.

In November 2021, we entered into an investment agreement with the Zhangjiagang Economic and Technological Development Zone Administration Committee. Under said investment agreement, we shall invest through one of our subsidiaries, in two new projects in Zhangjiagang Economic and Technological Development Zone ("ZETDZ"). The first project involves the acquisition of a plant Wuzhou from a stated-owned company controlled by ZETDZ. After renovation, we intend to use the plant to manufacture up to 330 million pcs/yr of sterile syringes and up to 50 million

10


 

pcs/yr of sterile vials. The second project envisages the construction of a new plant to be used to manufacture up to 360 million pcs/yr of bulk cartridges and up to 180 million pcs/yr of bulk vials, and SG Engineering business.

In December 2021, we entered into an Early Development Agreement (“EDA”) with the City of Fishers – Indiana, Fishers Town Hall Building Corporation and City of Fishers Redevelopment Commission envisaging the acquisition of an area of approximately 35.75 acres to be used for the construction of a new plant in Indiana (U.S.).

In addition to the aforementioned investment agreement, on February 23, 2022 Nuova Ompi signed the preliminary contract for the purchase of a brownfield in Latina (Italy) in proximity of other Stevanato Group facilities for a total consideration of approximately €16.0 million. The facility, after renovation, is expected to produce EZ-fill® syringes and vials.

Establishing new production plants for EZ-Fill® products represents a priority in light of the risks associated with our Piombino Dese (Italy) manufacturing facilities currently being the only ones devoted to the production of EZ-Fill® products which, in turn, exposes our business to risks of material disruption should any event affect the operation of such facilities. In general, such growth strategy and in particular the facilities expansion and the external acquisitions increase the complexity of our business and place a significant strain on our management, operations, technical systems, financial resources and internal control over financial reporting functions. Our current and planned personnel, systems, procedures and controls may not be adequate to support and effectively manage our future operations, especially as we employ personnel and maintain manufacturing facilities and distribution networks in several geographic locations.

We are also continuously expanding our product portfolio, and establishing and developing new products require significant management time and attention. If these products do not achieve the anticipated success or require greater levels of time and investment to reach the expected levels, it could adversely affect our business, financial condition and results of operations. Failure to appropriately integrate new products and business lines into our existing operations and systems can also affect the success of these products, and failure to adequately anticipate and plan for this integration could affect the success of these products and may also negatively impact our existing product offerings.

We may not successfully identify or integrate acquired businesses or assets into our operations or be able to fully recognize the anticipated benefits of businesses or assets that we acquire.

We consider acquisitions a useful instrument to complement our organic growth. We opportunistically explore acquiring other businesses and assets, and we have completed 3 acquisitions in the last five years, including: the acquisition of a 65% stake in the Danish SVM Automatik in February 2016 and of the remaining 35% in October 2021, the acquisition of the operating unit of Balda Group in March 2016 and the acquisition of Medirio in May 2016.

However, we may be unable to identify or complete promising acquisitions for many reasons, including any misjudgment of the key elements of an acquisition, competition among buyers, the high valuations of businesses in our industry, the need for regulatory and other approvals, lack of internal resources to successfully pursue all attractive opportunities and availability of capital. When we do identify and complete acquisitions, we may face financial, managerial and operational challenges, including diversion of management attention and resources needed for existing operations, difficulties with integrating acquired businesses, integration of different corporate cultures, increased expenses, potential dilution of our brand, assumption of unknown liabilities, potential disputes with the sellers and the need to evaluate the financial systems of and establish internal controls for acquired entities. Further, we seek out acquisitions of companies that maintain the same high quality standards that we maintain, and if we misjudge or overestimate a company’s product quality standards, we may not be able to use these products or implement the strategies that were the primary reason for the acquisition, which would lead to a significant loss both financially and in time spent by our teams trying to integrate the product or implement the strategy. There can be no assurance that we will engage in any additional acquisitions or that we will be able to do so on terms that will result in any expected benefits.

In addition, our ability to realize the benefits we anticipate from our acquisition activities, including any anticipated sales growth, cost synergies and other anticipated benefits, will depend in large part upon whether we are able to integrate such businesses efficiently and effectively. Integration is an ongoing process, and we may not be able to fully integrate such businesses smoothly or successfully, and the process may take longer than expected. Further, the integration of certain operations and the differences in operational culture following such activity will continue to

11


 

require the dedication of significant management resources, which may distract management’s attention from day-to-day business operations.

There may also be unasserted claims or assessments that we failed or were unable to discover or identify in the course of performing due diligence investigations of target businesses. While we normally negotiate representation and warranties and related indemnification in relation to such acquisitions, these may not be enough to cover our exposure if a significant liability arises in connection with any acquisition agreement. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result we may face unexpected liabilities that could adversely affect our business, financial condition and results of operations.

If we are unable to successfully integrate the operations of acquired businesses into our business, we may be unable to realize the sales growth, cost synergies and other anticipated benefits of such transactions, and our business, results of operations and cash flow could be adversely affected.

Our reputation, ability to do business and results of operations may be impaired by improper conduct by any of our employees, agents or business partners.

We cannot provide assurance that our internal controls and compliance systems will always protect us from acts committed by employees, agents or business partners of ours (including third-party suppliers, distributors or of businesses we acquire or partner with) that would violate U.S. and/or other national laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, export and import compliance, money laundering and data privacy. In particular, the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business. Any improper actions by our employees, suppliers and distributors or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in Italy, under Italian Legislative Decree No. 231 of June 8, 2001 (the “Decree 231”) pursuant to which a legal entity can be held liable to pay fines in connection with certain criminal offenses committed, inter alia, by its directors, officers or employees, the United States and in other jurisdictions, and any related shareholder lawsuits could lead to substantial civil and criminal, monetary and nonmonetary penalties and could cause us to incur significant legal and investigatory fees. In particular, pursuant to Decree 231, a defense can be established by an entity involved in a Decree 231 investigation, if such entity can prove, among others, that it adopted and properly implemented an organization, management and control model aimed at effectively preventing the commission of the criminal acts involved prior to such unlawful conduct having taken place. We approved and adopted the current version of our organization, management and control model provided by Decree 231 (“Model 231”) by means of a resolution of the board of directors dated April 7, 2021, and appointed the current supervisory body (the “Supervisory Body”) that supervises the functioning of and compliance with Model 231, and monitors and assesses the implementation status of preventive measures, with regular reports to the board of directors, in November 2020 and in April 2021. The adoption of organization and management models does not by itself exclude applicability of the penalties provided by Decree 231. In fact, upon commission of an offense resulting in administrative liability of the Group pursuant to Decree 231, the court will evaluate the models and their actual implementation. Failure to comply with Decree 231 could result in the imposition of criminal sanctions on our directors and/or monetary sanctions, other types of sanctions (e.g., interdictory sanctions, including prohibitions, confiscation of the price or profits deriving from the crime and publication of the judgment) and loss of confidence of our customer base as well as render us ineligible to participate in a public tender or result in the termination of a public contract already awarded, which could have a material adverse effect on the business, financial condition, results of operations and prospects of the Group.

In addition, a government may seek to hold us liable as a successor for violations committed by companies in which we invest or that we acquire.

We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards of conduct could occur that could have a material effect on our business, reputation, financial condition and results of operations.

12


 

Our global operations are subject to international market risks that may have a material effect on our liquidity, financial condition, results of operations and cash flows.

We operate manufacturing facilities in Italy, Slovakia, Denmark, Germany, United States, Mexico, China and Brazil, and sell and distribute our products in more than 70 countries. As part of our business strategy, we will continue to seek to expand our sales and market share in various international markets in which we currently operate and evaluate expansion opportunities into additional international markets. The economies of some of these markets differ from the economies of our core markets factors in Europe and in some cases present new and greater risks. Our financial results and operations are substantially dependent upon macro-economic and political conditions, particularly in Italy, Slovakia, Denmark, Germany, United States, Mexico, China and Brazil, where we operate manufacturing facilities. High levels of sovereign debt in certain countries (including Italy), combined with increasing inflation, weak growth, political instability and high unemployment rates, could lead to additional fiscal reforms (including austerity measures), sovereign debt restructurings, currency instability, increased counterparty credit risk, high levels of volatility and, potentially, disruptions in the credit and equity markets, as well as other outcomes, each of which, alone or combined with other factors, could have a material adverse effect on our business, results of operations, access to credit and capital markets and, therefore, our ability to implement our growth strategy.

The military actions undertaken by Russian military forces against Ukraine in February 2022 is creating and is likely to continue creating substantial disruptions in the region. Such military actions against Ukraine, as well as the measures adopted, or that may be adopted, by other countries in response to these events, including new and stricter sanctions by the European Union, the U.S., the United Kingdom and other countries and organizations against officials, individuals, regions, and industries in Russia, Ukraine and Belarus (or other countries that were to become involved), could have a material adverse effect on our operations. We are monitoring the conflict but do not and cannot know if this situation, which is unfolding in real-time, may escalate and result in broader economic and security conditions or in material implications for our business.

Macro-economic difficulties and political instability remain particularly evident in Italy. Since January 2012, Italy’s sovereign debt rating has been downgraded by Standard and Poor’s, Fitch Ratings and Moody’s Investor Service, reflecting their views as to Italy’s increasing vulnerability to external financing risks and the negative implications these could have for economic growth and public finances as well as fragile market confidence and deterioration in Italy’s near-term economic outlook. Any further downgrade of the Italian sovereign debt rating could create additional economic uncertainty and negatively impact Italy’s growth, which could in turn affect consumer confidence, discretionary spending and, consequently, demand for our products.

Furthermore, policies, measures, controls or other actions implemented by the governments of emerging markets or countries which we target for increased sales may restrict our business operations or harm our financial results. As a result, our revenue is exposed to risks inherent to the country where we operate or intend to operate including risks related to differing political, legal, regulatory and economic conditions and regulations.

As a multinational corporation, we are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations.

International markets contribute a substantial portion of our revenue, and we intend to continue expanding our presence globally. The exposure to fluctuations in currency exchange rates takes on different forms. International revenue and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenue and profitability when translated into Euro for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses often invoice third-party customers in currencies other than the one in which they primarily do business (the “functional currency”), especially U.S. Dollars and the Mexican Pesos. Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. Similarly, the current conflict between Russia and Ukraine has created extreme volatility in the capital markets and is expected to have further global economic consequences.

The deterioration of the sovereign debt of several countries, together with the risk of contagion to other, more stable, countries, has exacerbated the global economic crisis. In particular, a deterioration in general economic conditions

13


 

caused by instability in the Eurozone could have a material adverse effect on our business, financial condition, results of operations and prospects.

We are required to comply with a wide variety of laws and regulations and are subject to regulation by various federal, state and foreign agencies.

In all the jurisdictions in which we operate, we are subject to a number of laws, regulations and practices concerning, inter alia, the health and safety of our employees, the use, manufacture and importing of chemicals and the protection of the environment and natural resources.

In the event that the applicable laws and regulations were to change such that our products or our production processes were subject to greater regulatory control or restrictions, it could have a significant impact on our ability to market and sell our products and could require us to spend significant amounts to ensure and monitor compliance with such laws and regulations such that our business, financial condition and results of operations could be adversely affected. For instance, both the EU and the United States are considering to further restrict in the next years the use of ethylene oxide, the main sterilizing agent used in our production processes. If the use of ethylene oxide is further restricted, or completely banned, this would require us to identify new sterilizing agents and would have a negative impact on our financial condition and results of operations.

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products, the handling, transportation and manufacture of substances that could be classified as hazardous, laws governing government contracts and our business practices such as anti-corruption and antitrust laws. Although we believe that we comply in all material respects with applicable laws and regulations, there can be no assurance that a regulatory agency or tribunal would not reach a different conclusion concerning the compliance of our operations with applicable laws and regulations. In addition, there can be no assurance that we will be able to maintain or renew existing permits, licenses or other regulatory approvals or obtain, without significant delay, future permits, licenses or other approvals needed for the operation of our businesses. Furthermore, loss of a permit, license or other approval in any one portion of our business may have indirect consequences in other portions of our business if regulators or customers, for example, cease doing business with such other portion due to fears that such loss is a sign of broader concerns about our ability to deliver products or services of sufficient quality.

Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could have an adverse effect on our business, financial condition and results of operations. Failure to comply with these laws and regulations can lead to agency action, including warning letters, product recalls, product seizures, monetary sanctions, injunctions to halt manufacturing or distribution, restrictions on our operations, withdrawal of existing or denial of future approvals, permits or registrations, including those relating to products or facilities and civil and criminal sanctions. To the extent these agencies were to take enforcement action, such action may be made publicly available, and such publicity could harm our ability to sell these regulated products globally and may harm our reputation. In addition, such actions could limit the ability of our customers to obtain regulatory clearance or approval for their products in the United States or abroad and/or our customers may incur significant costs in obtaining or maintaining such regulatory clearances or approvals in the United States or abroad. In addition, any such failure relating to the products we provide exposes us to direct and third-party product liability claims as well as contractual claims from our customers, including claims for reimbursement for lost or damaged products, as well as potential recall liability, which could be significant. Customers may also claim loss of profits due to lost or delayed sales, although our contractual arrangements typically place limits on such claims. There can be no assurance that any such contractual limitation will be applicable or sufficient or fully enforced in any given situation.

Given the relevance of our activities in the healthcare sector, investments by non-Italian entities in the Company, as well as certain asset disposals by the Company, may be subject to the prior authorization of the Italian Government (so called “golden powers”).

Due to the relevance of our activities in the healthcare sector, it is not possible to exclude the recurrence of the conditions for the exercise, by the Italian Government, of the so called “golden powers”, aimed at impact the liquidity and value of the Shares. The golden power regime, set forth in (i) Law Decree no. 21 of March 15, 2012 (converted into law by Law no. 56 of May 11, 2012), as amended and supplemented (“Golden Power Decree”), (ii) Law Decree no. 105 of September 21, 2020 (converted into law by Law no. 133 of November 18, 2020), as amended and

14


 

supplemented, (iii) Law Decree no. 23 of April 8, 2020 (converted into law by Law no. 40 of June 5, 2020), as amended and supplemented, and (iv) Decree of the President of the Council of Ministers no. 179 of December 18, 2020, also cover the healthcare sector. The powers set forth in the Golden Power Decree include, inter alia, the powers to: (i) veto, or impose specific conditions on, the purchase by non-EU companies of shareholdings in companies having assets and relationships in sectors which are considered strategic (e.g., defense and national security, energy, transport and telecommunications, health, etc., the “Strategic Companies”), and (ii) veto, or impose specific conditions on, the adoption of certain corporate resolutions, acts or transactions by the same companies which may pose a threat to national security.

The Golden Power Decree requires companies to notify the office of the Italian Prime Minister within 10 days of: (i) any purchase by a non-EU entity of a stake in a Strategic Company resulting in the buyer acquiring control of such company pursuant to article 2359 of the Italian Civil Code and of the Italian Financial Act (TUF); and (ii) any resolution, act or transaction adopted by a Strategic Company resulting in a transfer of ownership, control or availability of strategic assets to a non-EU entity. Any resolution, act or transaction adopted by a Strategic Company, whose effect is to change the destination of a strategic asset, or a change in the corporate purpose of the Strategic Company. Furthermore, the regulation requires to notify the dissolution of the company or the amendment of certain provisions of their articles of association. The office of the Italian Prime Minister must exercise its power to veto the transaction or impose conditions within 45 days from the date of notice. In the interim, all rights related to the shares other than economic rights are suspended, and any decision adopted in violation of such suspension is null and void, but once the term has expired the relevant transaction can be completed. Should the office of the Italian Prime Minister veto the transaction, the buyer must sell the acquired shares or quotas within one year. As part of the emergency related to COVID-19, as a result of the Law Decree of April 8, 2020, no 23, these powers have been temporarily strengthened until December 31, 2021 by Law Decree of April 22, 2021 no. 52, converted with amendments by Law of June 17, 2021 no. 87.

The violation of the notification obligation or of the prescriptions imposed by virtue of the exercise of special powers, unless the fact constitutes a criminal offense, is subject to a pecuniary administrative sanction up to double the value of the transaction and in any case not less than one percent of the cumulative turnover achieved by the companies involved in the last financial year for which the financial statements were approved.

As a result, our ability to pursue commercial or industrial strategic resolutions, acts or transactions that involve the acquisition of, or the subscription for, our shares by a partner (or that imply an amendment to our shareholders’ structure) may be restricted by the Italian Government’s decision to exercise its special powers with respect to our business. Therefore, the application of the golden powers regime could have a material adverse effect on our business, results of operations, financial condition or prospects.

Furthermore, in the future, our shareholders’ ability to enter into change of control or takeover transactions may be impacted by the exercise by the Italian Government of its special powers under the golden power regime. Our shareholders may not be able to transfer their interests or such a transfer may be subject to conditions, which diminish the value of the transaction and discourage investments. This may limit our shareholders’ ability to benefit from the proceeds of certain proposed asset sales or acquisitions or business combinations, and may limit our shareholders’ ability to benefit from possible premiums connected to a proposed change of control transaction, tender offer or other strategic transactions.

The laws and regulations which we are subject to, such as U.S., EU and other anti-corruption laws, trade controls, economic sanctions and similar laws and regulations in the jurisdictions which we operate, are complex and the regulatory and political regimes under which we operate are volatile. Our failure to comply with the relevant laws and regulations could subject us to civil, criminal and administrative penalties and harm our reputation.

Certain of our operations are subject to U.S., EU and foreign anti-corruption and trade control laws and regulations, such as the Foreign Corrupt Practices Act (the “FCPA”), export controls and economic sanctions programs, including those administered by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”). As a result of doing business in foreign countries and with foreign partners, we may be exposed to a heightened risk of violating anti-corruption, export control, and sanctions laws and regulations.

15


 

The FCPA prohibits us from providing anything of value to foreign officials for the purposes of obtaining or retaining business or securing any improper business advantage. It also requires us to keep books and records that accurately and fairly reflect our transactions. As part of our business, we may deal with state-owned business enterprises, the employees of which are considered foreign officials for purposes of the FCPA. Other anti-corruption legislation which we may be required to adhere to, sets out wider prohibitions including against private bribery, which is also relevant to our business.

Economic sanctions and export controls may restrict our ability to conduct business with or in certain jurisdictions, individuals and entities. We are not a U.S. person and are not owned or controlled by one or more U.S. persons. We have in the past engaged in dealings with parties in Cuba, Iran, and Syria, and we have ongoing de minimis activities with parties in Iran and Cuba. We believe that such activities have been conducted in compliance with all applicable sanctions and export controls, and are implementing policies and procedures designed to ensure continued compliance. However, we cannot be certain that these safeguards will be fully effective in the future to ensure compliance, and the scope and reach of U.S. sanctions laws could also change over time.

The military actions undertaken by Russian military forces against Ukraine in February 2022 resulted in the imposition of financial and economic sanctions by the European Union, the U.S., the United Kingdom and other countries and organizations against officials, individuals, regions, and industries in Russia, Ukraine and Belarus. Such sanctions, together with any additional measure that may be adopted in connection with this situation, may, in various ways, constrain Russia and Ukraine related transactions. Our ability to engage in activity with certain consumer and institutional businesses in Russia and Ukraine or involving certain Russian or Ukrainian businesses and customers is dependent in part upon whether such engagement is restricted under any current or expected U.S., EU, U.K. or other countries sanctions and laws. Our ability to engage may be further impaired in the event other countries were to become involved in the conflict and, as result, be subjected to sanctions or similar restrictions.

Violations of anti-corruption, export control and sanctions laws and regulations are punishable by civil penalties, including fines, denial of export privileges, injunctions, asset seizures, debarment from government contracts and revocations or restrictions of licenses, as well as criminal fines and imprisonment. There can be no assurance that all of our employees, consultants, agents or other associated persons will not take actions in violation of these laws and regulations, and that our procedures will effectively prevent us from violating these regulations in every transaction in which we may engage or provide a defense to any alleged violation. In particular, we may be held liable for the actions that our local strategic partners take inside or outside of the United States, even though our partners may not be subject to these laws. Such a violation, even if our policies prohibit it, could have a material adverse effect on our reputation, business, results of operations and financial condition.

We are subject to product liability and other claims in the ordinary course of business.

Our business involves risk of product liability claims related to providing incorrect product information at the time of purchase, claims for defective containment solutions which may impair drug efficacy and other claims in the ordinary course of business. Furthermore, there may be product liability risks that are unknown or which become known in the future. We may also face claims raised by our present employees for injury deriving from the lifting and handling of loads and the use of heavy machinery, as well as claims raised by our present and past employees for injury and illness from hazardous substances used or present at certain of our facilities. Substantial, complex or extended litigation on any claim could cause us to incur significant costs and distract our management. For example, lawsuits by governmental authorities, employees, shareholders, suppliers, collaborators, distributors, customers, competitors or others could be very costly and substantially disrupt our business. Our exposure to such claims may increase as we seek to increase the geographic scope of our sourcing and sales activities and to the extent that we expand our manufacturing operations. We maintain insurance policies but we cannot assure you that our insurance coverage will be available in all pending or any future cases brought against us. Furthermore, our ability to recover under any insurance is subject to the terms and conditions of such insurance, as well as the financial viability of our and such third parties’ insurers, as well as legal enforcement under the local laws governing these arrangements. Insurance coverage in general or coverage for certain types of liabilities, such as product liability in developing markets, may not be readily available for purchase or cost-effective for us to purchase. Furthermore, many of our insurance policies are subject to deductibles and retentions. Accordingly, we could be subject to uninsured and unindemnified future liabilities requiring us to provide additional reserves to address such liabilities. An unfavorable result in a case for which adequate insurance or indemnification is not available could adversely affect our business, financial condition and results of operations.

16


 

Occasionally, we are also involved in disputes, litigation and regulatory matters incidental to and in the ordinary course of our business, including employment matters, commercial disputes, government compliance matters, environmental matters, and other matters arising out of the normal conduct of our business. Where merited, we will vigorously defend ourselves in such matters. There can be no assurance that the impact of any pending or future claims will not be material to our business, financial condition or results of operations.

We are exposed to credit risk on accounts receivable and certain prepayments made in the normal course of business.

Our average day sales outstanding for 2021 has been approximately 71.5 days, but a number of customers are pushing for longer payment terms (also offering no recourse discounting solutions). A substantial majority of our outstanding trade receivables are not covered by collateral or credit insurance. In addition, we may make advances to suppliers in the normal course of business. While we have procedures to monitor exposure to credit risk on trade receivables and other current assets, there can be no assurance such procedures will effectively limit our credit risk and avoid losses, which could have a material adverse effect on our financial condition and operating results.

We may be required to record a charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired.

We are required under IFRS to test goodwill for impairment at least annually and to review our goodwill, amortizable intangible assets and other investments, including those acquired through acquisition activity, for impairment when events or changes in circumstance indicate the carrying value may not be recoverable.

Factors that could lead to impairment of goodwill, amortizable intangible assets and other investments, including those acquired through acquisitions, include significant adverse changes in the business climate and actual or projected operating results and declines in the financial condition of our business. We may be required in the future to record additional charges to earnings if our goodwill, amortizable intangible assets or other investments become impaired. Any such charge would adversely impact our financial results.

If relations between China and the United States deteriorate, our business in the United States and China could be materially and adversely affected.

The relationship between China and the United States is subject to periodic tension. Changes in political conditions in the United States and China and changes in the state of China-U.S. relations are difficult to predict and could adversely affect our business. For instance, the U.S. administration has called for substantial changes to trade agreements and imposed significant increases on tariffs on goods imported into the United States, particularly from China. Other countries have responded similarly, with tariffs on goods entering their countries. We currently have facilities and sell products in China and have invested, and expect to continue investing, in the country, and if the Chinese government makes any changes to its laws or policy concerning foreign ownership of companies or assets located within China, or imposes any significant increases on tariffs on goods imported into or out of China, it could have a significant impact on our business and financial results.

If our employees were to engage in a strike or other work stoppage, our business, operating results and financial position could be materially adversely affected.

We employ approximately 4,652 employees, as at December 31, 2021, in multiple jurisdictions (approximately 51% of which based in Italy, 11% based in Mexico, 9% based in Germany, 8% based in Slovakia, 6% based in the U.S., Brazil and Denmark each and 4% based in China). A significant portion of our employees in Italy, Germany, Slovakia, Mexico, Denmark and China are covered by collective bargaining arrangements made either at the local or national level in their respective countries. Although we believe that our relations with our employees are satisfactory, no assurance can be given that this will continue. If disputes with our unions arise, or if our workers engage in a strike or other work stoppage, we could incur higher labor costs or experience a significant disruption of operations, which could have a material adverse effect on our business, operating results and financial position.

17


 

We are subject to tax laws, tariffs and potential tax audits in multiple jurisdictions that could affect our financial results.

We are subject to tax laws, tariffs and potential tax audits in multiple jurisdictions. The application and interpretation of these laws in different jurisdictions affect our international operations in complex ways and are subject to change, and some changes may be retroactively applied. Our tax liabilities in the different countries where we operate depend, in part, on transfer pricing and administrative charges among us and our subsidiaries. These arrangements require us to make judgments with which tax authorities may disagree, potentially resulting in the assessment of material additional taxes, penalties, interest or other charges to resolve these issues.

Transactions that we have structured in light of current tax rules could have material and adverse consequences for us if tax rules change. Tax audits, changes in tax laws, their application and interpretation or imposition of any new or increased tariffs, duties and taxes could increase our tax burden and materially and adversely affect our sales, profits and financial condition and could have an adverse effect on our business, net assets, or results of operations. Such factors could also cause us to expend significant time and resources and/or cause investors to lose confidence in our reported financial information.

We are exposed to Italian tax risks related to our multinational operations.

We operate in many different jurisdictions throughout the world, through our group companies. Over recent years, tax laws and practice applicable in various countries have become increasingly complex and sophisticated, particularly with respect to cross-border transactions. Italy has historically implemented a number of domestic provisions— including those implementing EU anti-abuse Directives and OECD principles – aimed at facing tax basis erosion schemes and allocation of income between associated enterprises adopted by multinational groups.

Italian Tax authorities are increasingly scrutinizing multinational groups based on these provisions by also enforcing exchange of information instruments in force with foreign tax authorities.

The combination of the above factors may lead to an increased likelihood of tax audits with respect, among other things, to: (i) tax residence, (ii) permanent establishment, (iii) transfer pricing, (iv) Controlled Foreign Company legislation, (v) taxation of dividends and capital gains derived upon interests held in companies located in low-tax Jurisdictions, (vi) withholding tax application on cross-border payments, and (vii) anti-hybrid mismatches. In any such case, depending on the specific circumstances, tax audits and/or tax litigations with the Italian tax authorities could result in tax liabilities and fines and penalties of significant amounts, which could be in excess of the amounts. We provide for in our financial statements for tax liabilities.

The application of indirect taxes could adversely affect our business and results of operations.

The application of indirect taxes, such as sales and use tax, value-added tax, provincial taxes, goods and services tax, business tax and gross receipt tax, to our business is a complex and evolving issue. Significant judgment is required to evaluate applicable tax obligations. As a result, amounts recorded may be subject to adjustments by the relevant tax authorities. In many cases, the ultimate tax determination is uncertain because it is not clear how new and existing statutes might apply to our business. A number of jurisdictions globally have introduced (or are looking to introduce) additional value added tax (or similar tax) calculation requirements as well as additional reporting, record-keeping, collection and remittance obligations on businesses like ours.

There can be no assurance that we will not be a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes. If we are a PFIC for U.S. federal income tax purposes, U.S. investors holding Shares may be subject to adverse federal income tax consequences.

A non-U.S. corporation will be a PFIC for U.S. federal income tax purposes for any taxable year in which either: (i) at least 75% of its gross income is “passive income” for purposes of the PFIC rules or (ii) at least 50% of the value of its assets (generally determined on the basis of a quarterly average) is attributable to assets that produce or are held for the production of passive income. Whether we are treated as a PFIC is a factual determination that is made on an annual basis after the close of each taxable year. This determination will depend on, among other things, the composition of our income and assets, as well as the value of our assets (which generally will be determined by reference to the public price of the Shares, which may fluctuate significantly), from time to time.

18


 

Based on the current and anticipated composition of our income, assets and operations and the price of the Shares , we believe we were not a PFIC for U.S. federal income tax purposes for our most recent taxable year and do not expect to be a PFIC for the current taxable year or for foreseeable future years. Nevertheless, there can be no assurance that we will not be a PFIC for the current taxable year or for any future taxable year. If we are treated as a PFIC for any taxable year during which a U.S. investor holds Shares, such U.S. investor could be subject to adverse U.S. federal income tax consequences. See “Income Tax Considerations—U.S. Federal Income Tax Considerations – Passive Foreign Investment Company.”

We are subject to restrictive covenants under certain financing agreements, which could impair our ability to run our business.

We have in place a number of financing agreements which include covenants (such as negative covenants that would restrict our ability to distribute dividends and exceed certain indebtedness ratios) which may restrict our ability to operate our business. Our failure to comply with these covenants, including as a result of events beyond our control, could result in a default or event of default that could materially and adversely affect our financial condition and results of operations. For additional information on applicable regulations see “Operating and Financial Review and Prospects—Liquidity and Capital Resources.”

The indemnification provisions of acquisition agreements by which we have acquired companies or businesses may not fully protect us, and we may face unexpected liabilities.

Certain of the acquisition agreements by which we have acquired companies or businesses require the former owners to indemnify us against certain liabilities related to the operation of the company or business before we acquired it. In most of these agreements, however, the liability of the former owners is limited, and certain former owners may be unable to meet their indemnification responsibilities. While we are protected by representation and warranties and related indemnification in relation to such acquisitions, these may not be enough to cover our exposure if a significant liability arose in connection with any acquisition agreement. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result we may face unexpected liabilities that adversely affect our business, financial condition and results of operations.

Our business depends on our ability to use and access information systems, and any failure to successfully maintain these systems or implement new systems to handle our changing needs could materially harm our operations.

We depend on standardized procedures and multiple information systems for our operations, customer service and quality and safety procedures. Furthermore, we rely on information technology systems to process, transmit, store and protect electronic information, including confidential customer, supplier, employee or other business information. Through our online platform, we collect and store confidential information that website users provide to us when submitting queries or job applications.

We use commercially available third-party technology solutions, software and software systems with some proprietary configurations. We also store data using third-party cloud services. Our information systems may be subject to damage or interruption from power outages, computer and telecommunications failures, computer viruses, security breaches, vandalism, catastrophic events, natural disasters, terrorist attacks, hackers and other security issues as well as human error. If our information systems are damaged, fail to work properly or otherwise become unavailable, particularly in light of the COVID-19 pandemic, we may incur substantial costs to repair or replace them, and we may experience a loss of critical information, customer disruption and interruptions or delays in our ability to perform essential functions and implement new and innovative services. If the cloud service providers we use were to experience unplanned downtime, delays or other issues delivering data to our information technology systems, including due to increased usage during the COVID-19 pandemic, it could adversely impact business operations. The compromising of our information systems or those with which we interact could harm our reputation and expose us to regulatory actions and claims from customers and other persons, any of which could adversely affect our business, financial condition and results of operations.

In addition, we may not have the necessary resources to enhance existing information systems or implement new systems where necessary to handle our increasing volume and/or our changing needs, and we may experience unanticipated delays, complications and expenses in implementing and integrating our systems. Any interruptions in

19


 

operations would adversely affect our ability to properly allocate resources and timely deliver our products, which could result in customer dissatisfaction. We currently rely on certain legacy systems that are no longer supported by their respective manufacturers, with only a small number of current employees able to maintain these systems. Any failure of these systems could have a business impact. The failure to successfully implement and maintain information systems could have an adverse effect on our ability to obtain new business, retain existing business and maintain or increase our sales and profit margins, any of which could adversely affect our business, financial condition and results of operations.

Cyber security risks and the failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions, could result in damage to our reputation, data integrity and/or subject us to costs, fines or lawsuits under data privacy or other laws or contractual requirements.

The integrity and protection of the data we hold is critical to our business. The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve. Implementing and maintaining compliance with applicable security and privacy regulations may increase our operating costs and/or adversely impact our ability to market our products and services to customers. Although our computer and communications hardware are protected through physical and software safeguards, they are still vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses and similar events. These events could lead to the unauthorized access, disclosure and use of non-public information. We could be subject to risks caused by misappropriation, misuse, leakage, falsification, system malfunction or intentional or accidental release or loss of information maintained in our information systems and networks and those of our OEM suppliers, including our cloud service providers. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these threats proactively or implement adequate preventative measures. If our computer systems are compromised, we could be subject to fines, damages, litigation and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business.

If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. The European Union and the United Kingdom have adopted comprehensive data protection and security laws. The European Union’s Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation), or the GDPR, which became effective in May 2018, as supplemented by national laws, and the UK GDPR (collectively, Applicable Data Protection Laws) impose strict requirements on controllers and processors of personal data in the European Economic Area, or EEA and the United Kingdom, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime and shortened timelines for data breach notifications. Applicable Data Protection Laws create new compliance obligations and increase financial penalties for noncompliance (including possible fines of up to 4% of global annual revenues for the preceding financial year or €20 million, or £17.5 million in the UK, (whichever is higher) for the most serious violations). Data privacy laws in the European Union and the United Kingdom are developing rapidly and, as a consequence of Brexit, the UK will be free to diverge from European Union data privacy laws. We may therefore be subject in the future to separate and additional data protection obligations to those that we are already subject to. This may result in additional costs and may necessitate changes to our business practices, which in turn may compromise our growth strategy and otherwise adversely affect our business, reputation, legal exposures, financial condition and results of operations. In recent years, the United States and European lawmakers and regulators have expressed concern over electronic marketing and the use of third-party cookies, web beacons and similar technology for online behavioral advertising. In the European Union, marketing is defined broadly to include any promotional material and the rules specifically on e-marketing are currently set out in the ePrivacy Directive which will be replaced by a new ePrivacy Regulation. While the ePrivacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process. The current draft of the ePrivacy Regulation imposes strict opt-in e-marketing rules with limited exceptions for business-to-business communications and significantly increases fining powers to the same levels as the GDPR. The UK has implemented the ePrivacy Directive into national law through the UK Privacy and Electronic Communications Regulation 2003, however it is unclear whether the UK will align itself to the ePrivacy Regulation, once implemented. This again

20


 

introduces the possibility we will be subject to, and required to comply with, a separate and additional legal regime with respect to data privacy, which may result in additional costs and may necessitate changes to our business practices, which in turn may compromise our growth strategy and otherwise adversely affect our business, reputation, legal exposures, financial condition and results of operations.

On August 20, 2021, the Standing Committee of the National People's Congress of the People's Republic of China promulgated the so-called Personal Information Protection Law (the “PIPL”), which entered into force on November 1, 2021. The PIPL, regarded as China’s version of the GDPR, aims at protecting the personal information rights and interests ensuring the orderly and free flow of personal information in accordance with the law, and promotes the reasonable use of personal information. The PIPL regulates how business operators may collect, use, process, share, and transfer personal information in China and supplements the existing data protection regime previously established by the Cybersecurity Law (“CSL”) and other fragmented national guidelines. Under the PIPL, personal information handlers must adopt necessary measures to safeguard the security of personal information. The PIPL further mandates that, in case of violations, the business operators can receive orders of rectification, suspension, termination of provision of services, or confiscation of illegal income.

There are also numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. Although we take measures to protect data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks, and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings and liability under federal or state laws that protect the privacy of personal information and may result in regulatory penalties.

Additionally, the Gramm-Leach-Bliley Act of 1999 (along with its implementing regulations) (the “GLBA”) restricts certain collection, processing, storage, use and disclosure by covered companies of certain personal information, requires notice to individuals of privacy practices and provides individuals with certain rights to prevent the use and disclosure of certain non-public or otherwise legally protected information. The GLBA also imposes requirements regarding the safeguarding and proper destruction of personal information through the issuance of data security standards or guidelines. In addition, many U.S. states in which we operate now or may operate in the future have laws that protect the privacy and security of sensitive and personal information. Certain U.S. state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. State laws are changing rapidly, and there is discussion in the U.S. Congress of a new federal data protection and privacy law to which we may be subject.

We are also reliant on certain manual processes for collecting and processing data, and any failures in these processes or failure to handle the data collected in accordance with relevant regulations could lead to enforcement actions. Complying with all applicable laws, regulations, standards and obligations relating to data privacy, security and transfers may cause us to incur substantial operational costs or require us to modify our data processing practices and processes. Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in significant fines, reputational damage and civil lawsuits, any of which may adversely affect our business, financial condition and results of operations. We may not be able to respond quickly or effectively to regulatory, legislative and other developments, and these changes may in turn impair our ability to commercialize our products or increase our cost of doing business. In addition, if our practices are not consistent or viewed as not consistent with legal and regulatory requirements, including changes in laws, regulations and standards or new interpretations or applications of existing laws, regulations and standards, we may become subject to audits, inquiries, whistleblower complaints, adverse media coverage, investigations, loss of export privileges, severe criminal or civil sanctions or reputational damage. Any of the foregoing could have an adverse effect on our competitive position, business, financial condition, results of operations and prospects.

The uncertain effects of climate change and potential climate change legislation could lead to business interruption, significantly increased costs and/or other adverse consequences to our business.

Climate change and potential climate change legislation may present risks to our operations, including business interruption, significantly increased costs and/or other adverse consequences to our business. Some of the potential

21


 

impacts of climate change to our business include physical risks to our facilities, water and energy supply limitations or interruptions, disruptions to our supply chain and impairment of other resources. In addition, if legislation or regulations are enacted or promulgated in the U.S., Europe or Asia or any other jurisdictions in which we do business that limit or reduce allowable greenhouse gas emissions and other emissions, such restrictions could have a significant effect on our operating and financial decisions, including those involving capital expenditures to reduce emissions, and our results of operations. Our manufacturing operations may not be able to operate as planned if we are not able to comply with new legal and regulatory legislation around climate change, or it may become too costly to operate in a profitable manner. Additionally, suppliers’ added expenses could be passed on to us in the form of higher prices and we may not be able to pass on such expenses to our customers through price increases.

Risks Relating to our Intellectual Property
Our trade secrets may be misappropriated or disclosed, and confidentiality agreements with directors, employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.

In addition to registered intellectual property rights, we rely on trade secrets and confidential know-how to protect our technology, especially because we believe that patent protection alone would not be sufficient to protect our business. However, trade secrets and confidential know-how are difficult to protect, and we have limited control over the protection of trade secrets and confidential know-how used by our licensors, collaborators and suppliers.

To protect this type of information against disclosure or appropriation by competitors, our usual practice is to require our directors, employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. Moreover, we put in place appropriate procedures to identify confidential material and restrict access to documentation. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, we have entered into, and may in the future enter into additional, collaborations with our competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known to our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and the outcome is unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Moreover, if any of our trade secrets and confidential know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. In some cases, we have entered into joint development agreements with our competitors that necessitate the sharing of certain trade secrets with these competitors. Given that our competitive position is based, in part, on our know-how and trade secrets, a competitor’s knowledge of our trade secrets or other unauthorized use or disclosure could impair our competitive position and may have an adverse effect on our business and results of operations.

If we are unable to obtain and maintain patent protection for our technology, products and potential products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.

Our success depends in part on our ability to secure and maintain patent protection with respect to our technology, current products and potential products, and any future potential products and technology we may develop. We seek to protect our proprietary position by filing or collaborating with our licensors to file patent applications related to our proprietary technologies, products and potential products.

The patent prosecution process is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, defend, enforce or license all necessary or desirable patents at a reasonable cost or in a timely manner in all desirable jurisdictions. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products in all such fields and jurisdictions.

It is possible that we will fail to identify patentable aspects of our research and development output or fail to take the necessary steps to seek patent protection before it is too late to obtain patent protection. We may not have the right to

22


 

control the preparation, filing, and prosecution of patent applications, or to maintain the rights to patents licensed from third parties. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our relevant proprietary products and technology, including current products, potential products, and any future potential products we may develop, in whole or in part. Our existing patents may have issued with claims that fail to cover our relevant proprietary products and technology, including current products, potential products and any future potential products we may develop, in whole or in part. In addition, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. Patents may not be granted for a number of reasons, including known or unknown prior art, deficiencies in the patent application or the lack of novelty or the underlying invention or technology. In addition, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in certain jurisdictions are not published until 18 months after filing or in some cases, at all. Therefore, we cannot be certain that we or our licensors were the first to make or file the inventions claimed in our owned or licensed patents or pending patent applications.

Even if patents do successfully issue and even if such patents cover our current products, current potential products and any future potential products we may develop, third parties may challenge their validity, ownership, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable or circumvented. We may become involved in proceedings challenging our owned or licensed patent rights, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or could limit the duration of the patent protection of our technology, products and potential products. Such proceedings also may result in substantial costs and require significant time from our management and employees, even if the eventual outcome is favorable to us. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our products, if approved, or practicing our own patented technology. Our competitors may also be able to circumvent our patents by developing similar or alternative potential products in a non-infringing manner.

Any of the foregoing could have an adverse effect on our competitive position, business, financial condition, results of operations and prospects.

We depend in part on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our potential products.

We are a party to certain license agreements for certain intellectual property and proprietary technology, and we may enter into additional agreements, including license agreements, with other parties in the future that impose certain obligations on us. If we fail to comply with our obligations to our licensors or any of our other current or future collaborators, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product, potential product or other technology that is covered by these agreements, which could adversely affect the value of the potential product being developed under any such agreement, or we may face claims for monetary damages or other penalties under these agreements. Termination of these agreements or reduction or elimination of our rights under these agreements may result in us having to negotiate new or reinstated agreements with less favorable terms, or cause us to cease or experience significant delays in the development and commercialization of our products, potential products or technologies and, our competitors or other third parties could have the freedom to market products and technologies identical or competitive to ours.

We may rely on third parties from whom we license proprietary technology to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that may be licensed to us.

The growth of our business may depend in part on our ability to acquire or in-license additional proprietary rights. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. In that event, we may be required to expend significant

23


 

time and resources to redesign our products, potential products or technologies or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis, which could adversely impact our business, financial condition, results of operations and prospects.

Disputes may arise regarding intellectual property subject to a license agreement and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our diligence, financial or other obligations under the relevant agreement, or we may face claims for monetary damages or other penalties under these agreements. Moreover, disputes may also arise over the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors or licensees and us and our partners. If disputes over intellectual property that we have licensed or any other dispute described above related to our license agreements prevent or impair our ability to use and enforce such intellectual property or maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected products, potential products or technologies. Any of the foregoing could have an adverse effect on our competitive position, business, financial condition, results of operations and prospects.

Third parties may assert claims against us alleging infringement, misappropriations or other violations of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of our products and potential products, or prohibit our use of proprietary technology or sale of products.

Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our products and other technologies without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. The various markets in which we operate can be subject to litigation regarding patents and other intellectual property rights. For example, our third-party collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use or misappropriate our proprietary information in such a way that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation. Our competitors have made substantial investments in patent portfolios and competing technologies, and may have applied for or obtained or may in the future apply for or obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.

We may be subject to third-party claims including patent infringement or similar adversarial proceedings or litigation in various jurisdictions. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product or potential product unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Third parties may obtain patents in the future and claim that use of our technologies, products and potential products infringes upon these patents. Additionally, because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our products, potential products or technologies may infringe. If any third-party patents issued from such applications were held by a court of competent jurisdiction to cover aspects of our products, potential products or technologies, the holders of any such patents may be able to prohibit our commercialization of the applicable product, potential product or technology until such patent expires or is finally determined to be invalid or unenforceable or unless we obtained a license.

In addition, defending such claims could cause us to incur substantial expenses and, if we fail, could cause us to pay substantial damages if we are found to be infringing a third party’s patent rights. Further, if a patent infringement suit is brought against us, our development, manufacturing or sales activities relating to the product, potential product or technology that is the subject of the suit may be delayed or terminated, as parties making claims against us may obtain injunctive or other equitable relief. As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights. These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights

24


 

may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our products, potential products or technologies, or forced to modify such products or potential products, or to cease some aspect of our business operations, which could harm our business significantly. We might also be forced to redesign or modify our products, potential products or technologies so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or such redesign or modification could be impossible or technically not viable.

Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, force us to face negative publicity, adversely impact prospective customers or prohibit us from manufacturing, importing, marketing or otherwise commercializing our products, potential products, services and technology. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors view these announcements in a negative light, the price of our ordinary shares could be adversely affected. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources, adversely affecting our ability to compete in the marketplace.

We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful and have an adverse effect on the success of our business.

Competitors or other third parties may infringe, misappropriate or otherwise violate our patents or other intellectual property. In addition, our third-party collaborators may use or misappropriate our intellectual property and proprietary information in such a way that could jeopardize our ownership and intellectual property rights. If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our products or potential products, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in certain countries, defendant counterclaims alleging invalidity or unenforceability are commonplace. Third parties may initiate invalidity proceedings even in the absence of infringement proceedings. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements. Interference or derivation proceedings provoked by third parties or brought by us or declared by the relevant patent authority may be necessary to determine the priority of inventions with respect to our patents or patent applications. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable.

If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products, potential products and other technology, which may allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or could require us to obtain license rights from the prevailing party in order to be able to manufacture or commercialize our products, potential products or technologies without infringing third-party patent rights. Even if a defendant does not prevail on a legal assertion of invalidity or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon, misappropriating or otherwise violating our intellectual property rights. Even if we were to successfully assert our patents or other intellectual property rights, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs or a court may not award remedies that sufficiently compensate us for our losses. The impact of public announcements of the results of hearings related to such awards on our business may be uncertain. Our patents and other intellectual property rights also will not protect our technology, products and potential products if competitors design around our protected technology, products and potential products without infringing our patents or other intellectual property rights.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

We rely on external law firms, their extended network of partners worldwide and their internal check procedures for patent maintenance and prosecution. In the event that we or our licensors fail to maintain the patents and patent

25


 

applications covering our products and potential products or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, it could create opportunities for competitors to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our products.

We enjoy only limited geographical protection with respect to certain patents, and we may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents covering our technology, products and potential products in all countries throughout the world would be prohibitively expensive, and even in countries where we have sought protection for our intellectual property, such protection can be less extensive than those in Europe and the United States. Competitors may use our and our licensors’ technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but where enforcement is not as strong as that in the European Union or the United States. These products may compete with our products, and our or our licensors’ patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many jurisdictions have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. In these jurisdictions, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be adversely impacted, which could have a material adverse effect on our business.

The legal system in certain foreign jurisdictions, particularly those in certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents and other intellectual property rights at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a commercial advantage from the intellectual property that we develop or license. Any of the foregoing could have an adverse effect on our competitive position, business, financial condition, results of operations and prospects.

We may be subject to claims that our employees, consultants, independent contractors or collaborators have wrongfully used or disclosed confidential information of their former employers or other third parties, and we may be subject to claims asserting ownership of what we regard as our own intellectual property.

We do and may employ individuals who were previously employed at universities or other life sciences companies, including our licensors, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, consultants, collaborators, independent contractors and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and to not use the know-how or confidential information of their former employer or other third parties, we may be subject to claims that we or our employees, consultants, collaborators or independent contractors have inadvertently or otherwise used or disclosed know-how or confidential information of their former employers or other third parties, or that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims, and if we fail, in addition to paying monetary damages, we may lose valuable personnel or intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, which could result in customers seeking other sources for the technology, or ceasing from doing business with us. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances, engage with scientific advisors or hire employees or consultants, any of which could adversely affect our business, including in terms of substantial cost, reputational loss and/or a distraction to our management and other employees.

26


 

If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies and protect our intellectual property rights.

If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies and protect our intellectual property rights. Our collaborators or strategic partners may have or may, in the future, develop, either alone or with others, products in related fields that are competitive with the products we have or may develop. In addition, our collaborators or strategic partners may use our intellectual property and proprietary information in such a way that could jeopardize our ownership and intellectual property rights. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner